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ABSTRACT 
 
JAN CATHERINE DENOFRIO:  Characterization of Platelet Function and 
Hemostasis in the Cib1-/- Mouse 
(Under the direction of Dr. Leslie Parise) 
 
 Platelet activation initiates platelet-platelet aggregation, platelet-extracellular 
matrix interactions and thrombus formation. Platelet aggregation requires activation 
of the αIIbβ3 integrin, an event regulated by the integrin cytoplasmic tails.  CIB1 
binds to the cytoplasmic tail of the integrin αIIb subunit.  CIB1 has been 
demonstrated to regulate αIIbβ3 activation in an acute setting.  We studied the Cib1-
/- mouse to determine if the chronic loss of CIB1 causes a defect in hemostasis.  
Plasma analysis exposed several significant differences in protein levels between 
the Cib1+/+ and Cib1-/- plasma.  Most notable were the increases in von Willebrand 
factor and soluble P-selectin.  To understand the effect of two pro-thrombotic 
proteins circulating at higher levels in the plasma, we examined bleeding time and 
arterial thrombus formation discovered no significant difference in thrombus 
formation or stability between the Cib1+/+ and the Cib1-/- mice.   
 Previous overexpression and knockdown studies in murine megakaryocytes 
from our lab demonstrated that CIB1 inhibits platelet integrin αIIbβ3 activation.  We 
analyzed Cib1-/- mice to determine the function of CIB1 in platelets in vivo.  We 
found that although these mice had no overt platelet phenotype, mRNA level of CIB1 
homolog CIB3 was increased in Cib1-/- megakaryocytes.  In vitro binding studies 
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demonstrate that recombinant CIB1, -2 and -3 bound specifically to an αIIb 
cytoplasmic tail peptide.  Subsequent protein modeling experiments indicated that 
CIBs 1-3 each have a highly conserved hydrophobic binding pocket.   
 Therefore, the potential exists for compensation by these CIB family members 
for loss of CIB1, thereby preventing pathologic thrombus formation in Cib1-/- mice. 
Interestingly, the Cib1-/- mouse does have a phenotype that may provide a model for 
studying critical levels of plasma proteins required for normal hemostasis. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Introduction to CIB1 
 Hemostasis is the process of blood clotting in response vascular injury.  
Misregulation of this physiological process can lead to either blood loss, or 
thrombotic vascular disease, which in either case, can be fatal.  Understanding 
the mechanisms involved in hemostasis provides insights for treating or 
preventing abnormal blood clotting (thrombus formation).  Integrin αIIbβ3, a 
transmembrane receptor on platelets and megakaryocytes, is critical for 
hemostasis and thrombus formation.  Activation of the integrin promotes soluble 
ligand binding and platelet aggregation.  The mechanisms that regulate αIIbβ3 
activation are not fully understood; therefore identification of potential regulatory 
molecules is necessary.    
 CIB1 (also known as calcium and integrin binding protein, CIB, KIP1, SIP 
and calmyrin) was identified in 1997 in our lab by a yeast two hybrid screen for 
proteins that bind to the cytoplasmic tail of the αIIb subunit of αIIbβ3 (Naik, Patel, 
& Parise, 1997).  However, the exact role of CIB1 in regulating platelet integrin 
αIIbβ3 activation has been unclear.  Our lab showed by direct genetic 
manipulation, that CIB1 is a negative regulator of agonist-induced αIIbβ3 
activation in megakaryocytes (Yuan et al., 2006b).  In another study, the 
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introduction of antibodies into platelets that block CIB1 function inhibited platelet 
spreading on immobilized fibrinogen (Naik & Naik, 2003a), suggesting that CIB1 
is required for platelet spreading.  Yet another group observed that introduction 
of a CIB1 binding peptide into platelets inhibited αIIbβ3 activation, leading this 
group to conclude that CIB1 induces αIIbβ3 activation. Therefore, acute change 
in CIB1 by genetic manipulations, antibody or peptide inhibition strongly suggests 
that CIB1 regulates integrin αIIbβ3 activation. To understand the potential 
function of CIB1 in vivo, we analyzed the Cib1-/- mouse to determine the effect of 
CIB1 loss on hemostasis and platelet activation. 
 
1.1.1 Basic properties of CIB1 
 CIB1 is a 22 kDa calcium binding protein that is expressed in several 
tissues and cell types (Shock et al., 1999).  Sequence and structural analysis 
demonstrates that CIB1 has 4 EF-hands and an N-terminal myristoylation site.  
CIB1 is homologous to other EF-hand containing proteins such as calmodulin 
and calcineurin B (Naik et al., 1997).  CIB1 also shares homology with several 
Ca2+-myristoyl switch neuronal calcium sensor proteins but is not solely 
expressed in neuronal cells (Gentry et al., 2005).  Furthermore, the hydrophobic 
binding channel found in EF-hand containing proteins is also present in CIB1 
(Gentry et al., 2005). Other protein homologs have been identified, providing 
evidence of a CIB family of 4 proteins (Gentry et al., 2005).  CIB1 is expressed 
many cell types (Shock et al., 1999), this implies (and has repeatedly proven) 
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that CIB1 interacts with other proteins and that CIB1 function is much more 
complex than simply regulating integrin αIIbβ3 agonist-induced activation. 
 
1.1.2 CIB1 binding partners 
 Since the initial yeast two hybrid screen, the CIB1/αIIb interaction has 
been detected by other assays including isothermal titration calorimetry (Shock et 
al., 1999; Yamniuk & Vogel, 2005), ELISA (Naik et al., 1997; Tsuboi, 2002; Yuan 
et al., 2006b), intrinsic tryptophan fluorescence (Barry et al., 2002; Yamniuk et 
al., 2005) and surface plasmon resonance (Vallar et al., 1999).  However, CIB1 
expression is not limited to αIIbβ3-expressing cells but is widely expressed in 
various cell types that do not express integrin αIIbβ3, thereby prompting the 
investigation of CIB1 interactions with other proteins (Naik et al., 1997; Shock et 
al., 1999).   
 Evidence has emerged demonstrating an important role of CIB1 as a 
kinase regulator.  CIB1 binds polo-like kinases SNK and FNK and inhibits SNK 
activity (Ma, Liu, Yuan, & Erikson, 2003).   CIB1 also binds focal adhesion kinase 
(FAK) and has been proposed to regulate FAK activation during platelet 
spreading on fibrinogen, through integrin αIIbβ3 (Naik et al., 2003a).  The 
interaction of CIB1 and p21-activated kinase (PAK1) a serine/threonine kinase 
has been studied in our lab.  CIB1 is required for PAK1 adhesion-induced 
activation (Leisner, Liu, Jaffer, Chernoff, & Parise, 2005) and mouse lung 
endothelial cells from the Cib1-/- mice have decreased levels of PAK1 activation 
after adhesion to fibronectin (Zayed et al., 2007).  The importance of CIB1 
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regulation of PAK1 activation was demonstrated by changes in PAK1-dependent 
cell migration that correlates directly with expression levels of CIB1 (Leisner et 
al., 2005).  Overexpression of CIB1 decreases cell migration 2.5 fold in REF52 
cells, likewise knocking down endogenous CIB1 leads to increases in haptotactic 
migration of HeLaS3 and REF52 cells (Leisner et al., 2005).  CIB1 can also bind 
and regulate the activity of 3-phosphoinositide-dependent protein kinase 1 
(PDK1) (Zhao in submission, 2007).  PDK1 is involved in cell survival and cell 
progression.  Wildtype CIB1 overexpression protected cells from apoptotic 
stimuli, while CIB1 mutants that are either unable to bind PDK1 or do not localize 
to the membrane, lose this apoptotic protection (Zhao in submission, 2007).  
Conversely, knockdown of CIB1 leads to decreased cell survival in response to 
apoptotic stimuli, while the overexpression of PDK1 rescues this phenotype 
(Zhao in submission, 2007). 
 Studies in the brain have demonstrated that CIB1 can bind to presenilin-2 
and the role of this interaction in Alzheimer’s disease is currently under 
investigation (Bernstein et al., 2005; Blazejczyk et al., 2005).  More recently, 
CIB1 was reported to bind the inositol 1,4,5-trisphosphate receptor (InsP3R) Ca2+ 
release channel (White, Yang, Monteiro, & Foskett, 2006).  The authors found 
that in single channel gating studies CIB1 could activate InsP3R (White et al., 
2006).  However, when CIB1 was overexpressed in PC-12 cells the amplitude of 
agonist-induced cytosolic calcium fluctuations decreased and in vitro pre-
exposure of CIB1 to InsP3R reduced the number InsP3R available for stimulation 
by inositol 1,4,5-trisphopshate (InsP3) (White et al., 2006). 
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1.1.3 CIB1 homology 
1.1.3.1 Homology to other EF-hand containing proteins 
 EF-hands are helix-loop-helix structural motifs that often bind calcium 
(Gifford, Walsh, & Vogel, 2007).  This calcium binding can induce a 
conformational change in the protein that enhances ligand affinity (Yap, Ames, 
Swindells, & Ikura, 1999; Shock et al., 1999; Tsuboi, 2002).  CIB1 has four EF-
hands, two C-terminal canonical Ca2+ binding EF-hands and two N-terminal non-
classical EF-hands (Fig. 1.1). CIB1 is homologous to other EF-hand containing 
proteins, calcinerin B (58%) and calmodulin (55%) (Naik et al., 1997).   CIB1 is 
also homologous to neuronal calcium sensor proteins KChIP1 (46%) and 
frequenin (43%).  Like KChIP1 and frequenin, CIB1 has an N-terminal 
myristoylation site, which may target the protein to the membrane (Gentry et al., 
2005).  It has been demonstrated however, that CIB1 myristoylation is not 
required for binding to membrane bound αIIbβ3 (Shock et al., 1999; Tsuboi, 
2002).  EF-hand III binds a calcium ion with a dissociation constant (Kd) near 1.9 
µM while EF-hand IV binds with a dissociation constant of 0.5 µM (Yamniuk, 
Nguyen, Hoang, & Vogel, 2004).  CIB1 can also bind Mg2+ at EF-III with a Kd of 
120 µM and this binding induces a similar conformational change as with Ca2+ 
binding (Yamniuk et al., 2004).  It has been proposed that CIB1 is Mg2+-bound in 
resting cells since the intercellular concentration of Mg2+ is higher than that of 
Ca2+ (Mg2+ concentration ~ 10-3 to 10-4 M, Ca2+ concentration ~ 10-7 to 10-8 M) 
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(Yamniuk et al., 2004; Yamniuk et al., 2005).  CIB1 protein stability is greater 
when bound to Ca2+ than Mg2+ (Yamniuk et al., 2004).   
 
1.1.3.2 CIB1 homology to other CIB family members 
Though CIB1 was the first CIB to be identified, it is not the ancestral original CIB.  
Homology screening determined that the Cib family consists of four genes (Cib1-
4) (Gentry et al., 2005).  There was only one Cib ancestral gene present through 
Drosophila evolution.  Cib1 diverged from the ancestral Cib between the 
evolution of Drosophila to Danio.  A genetic duplication occurred during the 
evolution of Danio to Xenopus that led to the current Cib2 and Cib3 genes, Cib2 
being more homologous to the ancestral Cib.  The Cib4 sequence did not 
emerge until mammalian evolution.  Homology to Caernorhabditis ancestral CIB 
as determine by BLAST searches are shown in (Fig. 1.2) 
 Previous studies of the sequences of CIB family members indicted that 
CIB2 shares 59% homology to CIB1 while CIB3 and CIB4 are 62% and 64% 
homologous to CIB1, respectively (Fig 1.3) (Gentry et al., 2005).  CIB2 has been 
identified in HEK293 cells by mass spectrometry but currently there is no other 
literature on the protein (Mayhew et al., 2006).  There is no published data on 
CIB3 and CIB4 protein expression.  Using the Prosite database 
(http://ca.expasy.org/prosite/) (de Castro et al., 2006) and Prosite My Domains 
Image Creator (http://ca.expasy.org/tools/mydomains/), potential functional 
domains of CIBs1-4 can be mapped (Fig. 1.4).  Based on Prosite analysis, EF-
hands are found in all CIB proteins.  There is one N-terminal incomplete EF-hand 
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predicted in CIBs1-3 but predicted calcium binding EF-hands at the C-terminus of 
all CIB proteins.CIB2 and CIB3 have more acidic residues between helices H4 
and H5 (EF-hand 2 in CIB1) and have the potential to bind a third calcium 
(Gentry et al., 2005).  Human CIB1, -2 and -3 each has an N-terminal 
myristolyation site (Fig 1.4).  Other predicted post-translational modification 
sequences predicted by this program include an N-glycosylation site in CIB1 and 
CIB2, and casein kinase II phosphorylation sites in CIB1-4. In addition, CIB1, -3 
and -4 have protein kinase C phosphorylation sites (de Castro et al., 2006). 
 
1.1.4 Structure of CIB1  
 In 2004, the structure of CIB1 was solved by our lab (Gentry et al., 2005) 
and another (Blamey, Ceccarelli, Naik, & Bahnson, 2005).   Both structures are 
based on human CIB1 with an N-terminal truncation of the first eight amino acids 
(CIB1∆1-8); however, the two structures depict distinct differences in tertiary and 
quaternary structure.  Gentry et al. describe CIB1 as a monomeric protein with a 
large hydrophobic binding pocket (Fig 1.5) (Gentry et al., 2005).  In contrast, 
Blamey et al. report a structure that aligns head to toe to create a dimer and is 
potentially redox regulated (Blamey et al., 2005).  The Gentry et al. CIB1 
structure was resolved at 2.0 Å and the Blamey et al. structure was resolved at 
2.3 Å.  Currently, the monomeric form of CIB1 is more accepted as 
sedimentation equilibrium, gel filtration and diffusion nuclear magnetic resonance 
(NMR) spectroscopy all provide data supporting a single oligomeric state (Gentry 
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et al., 2005; Sobczak et al., 2005; Weljie, Yamniuk, Yoshino, Izumi, & Vogel, 
2003).   
 
1.1.5 Hydrophobic binding pocket of CIB1 
 
 The hydrophobic binding pocket of CIB1 is the putative αIIb binding site.  
Interestingly, the C-terminal extension of CIB1 partially blocks the hydrophobic 
binding pocket.  Vogel and colleagues investigated if and how the C-terminus 
could be affecting ligand binding to the hydrophobic pocket (Fig. 1.6) (Yamniuk, 
Ishida, & Vogel, 2006).  Using solution NMR spectrometry, optical spectrometry 
and isothermal titration calorimetry (ITC) they determined that αIIb peptide 
binding causes both large chemical shift perturbations and increased the 
flexibility of the C-terminus (Yamniuk et al., 2006).  This implies that the C-
terminal tail moves upon binding, expanding the depth and size of the 
hydrophobic pocket.  To test this conclusion, Yamniuk et al. deleted the last 12 
amino acids of CIB1, thereby removing the H10 helix (CIB1∆H10).  They 
identified the exposed hydrophobic surfaces of both full-length and mutant CIB1 
by steady state fluorescence spectroscopy and found that CIB1∆H10 displays a 
larger hydrophobic surface than full-length CIB1 (Yamniuk et al., 2006).  Taken 
together the results of these experiments indicate that the C-terminal extension 
of CIB1 may act to enhance target specificity, meaning only specific sequences 
displace the C-terminal tail and bind CIB1 (Yamniuk et al., 2006).  
 
1.1.6 Cib1-/- mouse model to study the effect of the chronic loss of CIB1 
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 Cib1 is located on human chromosome 15 and mouse chromosome 7.  
Mouse Cib1 contains seven exons and six introns.  To generate the knockout 
mouse, Dr. Weiping Yuan from our lab replaced genomic DNA (all of exon 4 and 
most of exon 5) with the reversed neomycin gene (Yuan et al., 2006a).  No other 
protein encoding genes align in the area covered by Cib1 on the + or – strand.  
The Semaphorin 4b gene is adjacent to the Cib1 gene, but does not overlap. 
 The general health and development of the Cib1-/- mice is normal; 
however, Cib1-/- male mice are sterile (Yuan et al., 2006a).  This phenotype is not 
present in the male Cib1+/- mice and the female reproduction in both Cib1+/- and 
Cib1-/- mice is normal.  The sterility defect in the Cib1-/- mouse occurs during the 
haploid stage of spermatogenesis (Yuan et al., 2006a).  The exact mechanism 
causing this defect is currently unknown. 
 Upon further characterization of the Cib1-/- mice, we discovered a defect in 
angiogenesis (Zayed et al., 2007).  More specifically, the loss of CIB1 results in 
endothelial cells that display decreased migration, PAK1 and ERK1/2 activation 
and matrix metalloproteinase 2 expression (Zayed et al., 2007).  These 
decreases result in defects in ischemia-induced pathologic angiogenesis in the 
Cib1-/- mouse (Zayed et al., 2007). 
 
 
1.2 BASICS OF HEMOSTASIS 
 
 Hemostasis is the physiologic process of blood clotting at areas of 
vascular injury.  Upon damage to the endothelial cells lining a blood vessel, 
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adhesive extracellular matrix proteins (ECM) become exposed such as collagen 
and von Willebrand factor (vWF).  Platelets are attracted to these matrix proteins 
as they express several adhesion receptors that bind to individual ECM proteins.  
Glycoprotein (GP) VI binds collagen (Massberg et al., 2003; Nieswandt et al., 
2001; Nieswandt & Watson, 2003) and the GPIb/IX/V complex binds vWF 
(Ruggeri, De Marco, Gatti, Bader, & Montgomery, 1983; Ruggeri, 1988; Ruggeri, 
Zimmerman, Russell, Bader, & De Marco, 1992).  These initial contacts between 
the platelets and the ECM result in platelet rolling along the damaged 
endothelium.  These contacts are transient but serve to activate platelets and 
initiate thrombus formation.    Once activated, platelets release soluble pro-
coagulant proteins and agonists, which act as a signal to recruit more platelets.  
As platelets continue to roll along the endothelium, stronger adhesive reactions 
cause platelets to stop and spread to cover the exposed ECM.   Integrins, which 
are heterodimeric adhesion receptors, change conformation and have increased 
ligand affinity upon agonist-induced activation.  Active integrin α2β1 binds 
collagen (Nieswandt et al., 2003) and integrin αIIbβ3 binds vWF (Hato, Pampori, 
& Shattil, 1998; Kasirer-Friede et al., 2004).  At this time, platelets also interact 
with each other to form aggregates.  Platelets aggregate by binding fibrinogen, 
the major αIIbβ3 ligand.   One integrin αIIbβ3 from one platelet adheres to the 
same fibrinogen molecule as another αIIbβ3 on a different platelet.  Since 
integrin αIIbβ3 is highly populated on the platelet surface, these fibrinogen links 
result in stable aggregates (Parise, 1999; Phillips, Charo, & Scarborough, 1991).    
Aggregates build up from the ECM-bound platelets and the combination results 
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in stable thrombus formation, known commonly as a blood clot.  Not surprising, 
the process of clot break-down is just as methodical.   
 A careful balance of pro- and anti-coagulant proteins is essential in 
hemostasis (Fig.1.7).  A pathologic state can result when pro-coagulant proteins 
are unable to initiate and stabilize a thrombus, or if anticoagulant proteins are 
unable to disassemble the clot.   Insufficient surface receptor expression on 
platelets or endothelial cells, or defective ECM proteins or coagulation clotting 
factors can lead to a hemorrhagic state.  For example, patients with Glanzmann 
Thrombasthenia have a defect in integrin αIIbβ3 expression or function.  These 
patients have prolonged bleeding because they cannot aggregate properly 
(Phillips, Jenkins, Luscher, & Larrieu, 1975).   On the other side of the spectrum, 
patients with type 2B von Willebrand Disease have increased vWF binding to 
platelets, which results in spontaneous aggregation.  The hyper-aggregation 
results from increased affinity of vWF to GP1b (Lillicrap, 2007). 
 Cardiovascular disease is the leading cause of death in the developed 
world (Nieswandt, Aktas, Moers, & Sachs, 2005).  In the United States, 
cardiovascular disease is associated with almost 40% of all deaths (Rosamond 
et al., 2007). Pathologic thrombus formation can lead to cardiovascular disease 
when the thrombus size occludes blood flow.  This usually occurs in vessels 
damaged by atherosclerotic plaques that have constricted vessel size and 
elasticity, and provide highly pro-thrombotic and pro-inflammatory environment.  
Thrombi can also embolize, causing a downstream blockage in smaller vessels.  
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Common thrombus-related cardiovascular diseases include myocardial 
infarctions and strokes.    
 
1.2.1 Plasma proteins 
 Soluble proteins in plasma are also essential for aggregate formation and 
thrombus stabilization.  Some plasma proteins such as vWF, P-selectin, 
fibrinogen and thrombospondin, are stored intracellular granules in cells and are 
released or exposed upon cellular activation; this could potentially provide a 
method of regulation to preventing unnecessary thrombus formation.  Platelets 
and endothelial cells exocytose their storage granules (α-granules and Weibel 
Palade bodies respectively) and either release their contents into the plasma or 
onto the extracellular plasma membrane surface.   High levels of pro-thrombotic 
proteins in plasma have been proposed to be markers of platelet or endothelial 
cell activation and could provide a measure of vascular health and integrity 
(Blann, Faragher, & McCollum, 1997; Blann & Lip, 1997; Guray et al., 2004).  
Increased plasma P-selectin levels alone correlate with myocardial infarction 
(Blann et al., 1997; Ikeda et al., 1994), thrombotic consumptive platelet disorders 
(Chong et al., 1994; Katayama et al., 1993), and peripheral arterial occlusive 
disease (Galkina & Ley, 2006).  Furthermore, mice genetically engineered to 
express increased levels of soluble P-selectin have faster clotting times in a P-
selectin concentration-dependent manner (Andre, Hartwell, Hrachovinova, 
Saffaripour, & Wagner, 2000). 
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1.2.2 Mouse models used in hemostatic research 
 
 Mouse models have provided great insight into the mechanisms of normal 
hemostasis and hematological disorders.  Von Willebrand Disease (vWD) is the 
most common inherited bleeding disorder (Rodeghiero, Castaman, & Dini, 1987).  
The disease results from mutations in the vWF gene and can be classified into 
three types; 1, 2 and 3.  Type 2 has four subtypes; 2A, 2B, 2M and 2N.  As 
mentioned earlier, the physiological functions of vWF include tethering platelets 
to endothelial cells or exposed ECM and stabilizing platelet aggregates.  Another 
important function of this protein is to bind Factor VIII and prevent its 
degradation.  The vWF-/- mouse most closely mimics Type 3 vWD, displaying 
spontaneous bleeding and reduced Factor VIII levels (Denis et al., 1998).  
Research on the vWF-/- mouse demonstrated that vWF is necessary in thrombus 
stability and is vital in high shear stress  (Ni et al., 2000).  Studies using gene-
transfer to rescue the phenotype of the vWF-/- mouse have shown that it may be 
possible to correct or at least ameliorate the bleeding disorders associated with 
vWD (Pergolizzi et al., 2006).   
 The model for Glanzmann Thrombasthenia has also proven to be 
invaluable for understanding and potentially treating the disease.  The integrin 
subunit β3-/- mouse is used as a model for Glanzmann Thrombasthenia (GT) 
because platelets from these mice have a similar phenotype to those of GT 
patients (Hodivala-Dilke et al., 1999).   Investigators were able to explore the 
possibility of gene therapy to treat the disease by utilizing the platelet-specific 
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αIIb promoter to express the β3 gene (Fang et al., 2005).  The successful 
expression of β3 did, in fact, improve bleeding times (Fang et al., 2005).   
 Previous methods to investigate hemostasis in humans involved ex vivo 
experiments.  Human platelets can be isolated from whole blood and studied by 
aggregation, flow cytometry and adhesion to immobilized ligand.  Though blood 
volume can be an issue, these types of assays can also be easily performed with 
mouse models, but the principal motive to use mice to study hemostasis is to 
visualize a thrombus or blood clotting in real time.  
 Intravital microscopy has been an invaluable tool in hemostasis and 
thrombosis research. Studies on platelet aggregation, transient (“rolling”) or firm 
adhesion along with thrombus stability have all been studied in vivo by intravital 
microscopy (Celi et al., 2003; Dubois, Panicot-Dubois, Gainor, Furie, & Furie, 
2007; Falati et al., 2004; Falati et al., 2006; Furie & Furie, 2006; Furie & Furie, 
2007; Sim, Flaumenhaft, Furie, & Furie, 2005).  Other valuable methods of 
research are based on visual observations of vessel integrity such as measuring 
bleeding times or thrombus-dependent vessel occlusion at sites of inflicted injury.  
These experiments require larger blood vessels than those needed for intravital 
microscopy but still provide an excellent visual of thrombus formation and 
stability (Denis & Wagner, 2007).   
 Of course all results from knockout or transgenic mice must take into 
account the possibility of compensation by proteins with highly similar functions.  
In addition,  the lack of a phenotypic change in a genetically altered mouse does 
not mean there is no function of the protein or it could indicate that the function of 
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the protein is non-essential to hemostasis (Hynes & Wagner, 1997).  It should 
also be noted that mice are not the only valuable animal models of thrombosis.  
In fact, a pig model of vWD demonstrated that soluble vWF circulating in the 
plasma, opposed to platelet stored vWF, was essential in arterial thrombosis 
(Nichols et al., 1991; Nichols et al., 1995).  Other important studies have used 
guinea pigs (Andre et al., 1996b; Andre et al., 1996a), rats (Kurz, Main, & 
Sandusky, 1990), dogs (Coller & Scudder, 1985), zebrafish (Jagadeeswaran, 
Gregory, Day, Cykowski, & Thattaliyath, 2005; Thattaliyath, Cykowski, & 
Jagadeeswaran, 2005) and primates (Gruber & Hanson, 2003; Wu et al., 2002; 
Wu, Meiring, Kotze, Deckmyn, & Cauwenberghs, 2002; Gruber et al., 2007). 
 
1.2.3 Other methods of hemostatic research  
 
(The following section, 1.2.3, includes excerpts from the review by Lui et al. 2007.  I am 
the co-first author of this review and contributed significantly with both writing and 
editing.) 
 
 “Because circulating platelets are anucleate, direct and rapid genetic 
manipulation of platelets to study molecular mechanisms is not currently 
possible.  In addition, cells other than platelets or primary megakaryocytes 
(platelet precursors) do not have the ability to perform platelet specific functions 
such as agonist-induced αIIbβ3 activation (Fig. 1.8).  Thus, even megakaryocyte-
like cell lines, which have many platelet-like properties, including αIIbβ3 
expression, do not respond to common platelet agonists to activate the 
fibrinogen-binding capacity of αIIbβ3, perhaps due to a lack of proper activation 
machinery, which is still being defined (Shattil & Leavitt, 2001).  Therefore, while 
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nucleated megakaryocyte-like cell lines can be genetically manipulated, they are 
not useful via this approach for determining whether any given target molecule 
plays a role in αIIbβ3 activation or platelet aggregation.  Because of these 
limitations, some investigators have used alternative approaches such as 
expressing artificial, constitutively active versions of αIIbβ3 in CHO cells in order 
to explore mechanisms of turning integrins “off”, but these have significant 
limitations because they do not mimic or involve natural pathways of αIIbβ3 
activation in platelets (Han et al., 2006; Hughes et al., 1997; Shattil et al., 2001).  
Knockout and transgenic mice can be generated to allow study of target 
molecules in the platelets of these mice, but these approaches are neither rapid 
nor high-throughput.  Finally, several labs have exploited the fact that 
megakaryocytes derived from bone marrow, fetal livers, or in culture from 
embryonic stem (ES) cells are nucleated and can therefore be directly genetically 
manipulated.  These types of megakaryocytes can be matured in culture to the 
point that they express αIIbβ3 and respond to agonists to activate the fibrinogen-
binding capacity of the integrin (Shattil et al., 2001).  Using primary murine 
megakaryocytes we recently determined that a protein, CIB1, functions as a 
direct, endogenous inhibitor of αIIbβ3 activation (Yuan et al., 2006b).  Thus, 
megakaryocytes provide a useful model system, sharing many properties with 
platelets and representing the best directly genetically manipulatable platelet-like 
system to date.  Finally, ES or CD34+ progenitor cells in culture can generate 
platelet-like particles, offering the potential to genetically manipulate platelet 
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protein expression (Fujimoto, Kohata, Suzuki, Miyazaki, & Fujimura, 2003; 
Ungerer et al., 2004). (Liu et al., 2007)” 
 “Since integrin αIIbβ3 is only expressed on platelets and megakaryocytes, 
and as mentioned above “platelets are not amenable to direct genetic 
manipulation, megakaryocytes have been used to study integrin αIIbβ3 signaling.  
Proteins affecting αIIbβ3 signaling have been studied by overexpressing or 
knocking down their expression in bone marrow or ES cell-derived 
megakaryocytes via Sindbis virus, retrovirus and lentivirus-mediated 
transduction.  Using a Sindbis virus expression system, our lab and others have 
successfully overexpressed many proteins and have determined the effects of 
these proteins on agonist-induced activation of αIIbβ3.  Initially, the Shattil lab 
demonstrated that Sindbis virus-mediated expression of Tac-integrin β3 
cytoplasmic tail selectively inhibited αIIbβ3 activation in response to PAR4 
peptide, ADP, or epinephrine (Shiraga et al., 1999).  Based on their pioneering 
work, our lab set up a similar primary megakaryocytes system to test the function 
of CIB1, H-Ras, and other molecules that have been implicated in αIIbβ3 
activation.  We found that overexpression of CIB1-EGFP completely inhibited 
agonist-induced fibrinogen binding when compared to either overexpression of 
EGFP alone or untransduced megakaryocytes (Yuan et al., 2006b).  However, 
when we overexpressed a CIB1 mutant protein (CIB F173A-EGFP) containing a 
single Phe to Ala substitution that does not bind to αIIb cytoplasmic tail (Barry et 
al., 2002), these transduced megakaryocytes were unable to suppress PAR4 
peptide-induced αIIbβ3 activation (Yuan et al., 2006b).  These results suggest 
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that CIB1 is a potential negative regulator of αIIbβ3 activation upon agonist 
stimulation.  As mentioned above, we also knocked down endogenous CIB1 via 
siRNA in bone marrow-derived megakaryocytes and observed a small but 
statistically significant increase in fibrinogen binding to megakaryocytes.  These 
data complement the CIB1 overexpression studies and suggest a negative 
regulatory role for CIB1 in modulating αIIbβ3 activation (Yuan et al., 2006b).   
Another molecule proposed to be a negative regulator of integrin activation is H-
Ras (Fujimoto et al., 2003; Hughes et al., 1997; Hughes et al., 2002; Ramos, 
Kojima, Hughes, Fenczik, & Ginsberg, 1998; Sethi, Ginsberg, Downward, & 
Hughes, 1999).  Ginsberg and colleagues, using a constitutively active chimeric 
integrin expressed in a CHO cell system, found that H-Ras suppressed integrin 
activation (Hughes et al., 1997; Hughes et al., 2002).  Early studies 
demonstrated that H-Ras suppressed integrin activation via the Raf-MEK-ERK 
pathway (Fig 1.9) (Hughes et al., 1997).  However, later studies showed ERK 
activity was not necessary for H-Ras suppression of integrin activation (Hughes 
et al., 2002).  I sought to investigate the role of H-Ras on endogenous integrin 
αIIbβ3 activation using megakaryocytes overexpressing constitutively active H-
Ras via retrovirus.  Presumably, if H-Ras negatively regulated integrin function, 
agonist-induced fibrinogen binding would be decreased in cells overexpressing 
constitutively active H-Ras12V versus vector alone.  Contrary to the 
hypothesized results, our data demonstrated that H-Ras did not suppress integrin 
activation.  In fact, as shown in Figure 1.10, the cells overexpressing 
constitutively active H-Ras12V exhibited a trend of increased agonist-induced 
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αIIbβ3 activation.  Furthermore, the presence of PMA, a known activator of H-
Ras (Chang et al., 2005; Dower et al., 2000; Lorenzo et al., 2001), did not 
suppress αIIbβ3 activation in megakaryocytes overexpressing the vector alone.  
Therefore, these results do not support a negative regulatory role for H-Ras in 
agonist-induced αIIbβ3 activation.  While both cells are valid systems, the 
differing results between the bone marrow-derived megakaryocyte system and a 
chimeric integrin-CHO cell system highlight the strong role of the intracellular 
environment in signaling studies.  Therefore, it is important to understand the role 
of the endogenous proteins in their natural cellular environment whenever 
possible”(Liu et al., 2007).  
 
 
1.3  CIB1 AND INTEGRIN αIIbβ3  
 
(The following section section 1.3 contains excerpts from the review by Leisner et al., 
2007.  I contributed significantly in both the writing and editing of this review.) 
 
  “Integrin activation is essential for platelet function and as a result, the 
molecular mechanisms that regulate integrin activation have been the focus of 
intense study.  In general, integrins are ubiquitous transmembrane α/β 
heterodimers that mediate cell–cell and cell–matrix interactions, which are vital 
for both normal and pathophysiological processes. At present, there are 18 α and 
8 β subunits that noncovalently combine to form at least 24 distinct integrins. 
Structurally, integrin receptors are largely extracellular, with each subunit 
possessing a single-pass transmembrane domain and a relatively short 
cytoplasmic domain (from 20 to 70 amino acids). Integrin αIIbβ3 is the most well 
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characterized integrin family member and studies involving integrin αIIbβ3 have 
provided invaluable insight into mechanisms of integrin activation. Furthermore, 
many of the functional properties of αIIbβ3 have proved widely applicable to 
other integrin receptors. Like αIIbβ3, ligand binding to other integrins is regulated 
by intracellular signaling. The exact mechanisms by which intracellular signals 
culminate at the cytoplasmic face and lead to integrin activation and ligand 
binding still remain unclear.  
 Central to the propagation of inside-out and outside-in signaling events 
are the integrin transmembrane and cytoplasmic domains that are thought to play 
ian important role in regulating integrin affinity states (Ginsberg, Partridge, & 
Shattil, 2005). Early mutational studies demonstrated that deletion of either the α 
or β cytoplasmic domain results in integrin activation (Hughes, O'Toole, Ylanne, 
Shattil, & Ginsberg, 1995; O'Toole et al., 1991), as do point mutations in the 
conserved GFFKR motif within the αIIb membrane proximal region (O'Toole et 
al., 1994). Additional studies have provided evidence for an interaction between 
the membrane-proximal regions of the α and β cytoplasmic tails through a salt 
bridge between a conserved Arg995 in the α tail and an Asp723 in the β tail, 
which is thought to maintain the integrin in an inactive state (Hughes et al., 
1996). While the αIIb and β3 cytoplasmic tails were reported to form complexes 
in solution (Vinogradova et al., 2002) and to form homodimers in lipid micelles (Li 
et al., 2001), other studies failed to demonstrate any interaction between the 
cytoplasmic tails (Ulmer, Calderwood, Ginsberg, & Campbell, 2003). These 
differences may in part be due to the varying length of the isolated integrin 
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cytoplasmic domains used in each study. In subsequent nuclear magnetic 
resonance (NMR) studies, a low-affinity interaction was detected only with full-
length cytoplasmic tails (Li et al., 2001; Vinogradova et al., 2002), suggesting 
additional sites of interaction between the integrin subunits. A recent study by Ma 
et al. (Ma et al., 2006) used mutational analysis to demonstrate that distinct 
regions within the α and β tails cooperate to regulate integrin activation. 
Specifically, mutation of αIIb residues V990F992R995 within the membrane- 
proximal KVGFFKR motif was shown to disrupt the electrostatic and hydrophobic 
bonds between the α and β tails, leading to extensive integrin activation.  NMR 
spectroscopy also revealed that a naturally occurring S752P mutation (Chen et 
al., 1992) disrupted a C-terminal helix within the β3 tail and partially suppressed 
integrin activation.  
 Recent evidence indicates that the integrin α and β transmembrane 
domains also play an important role in the regulation of integrin activation. 
Mutation of various residues within the transmembrane helical domains results in 
integrin activation (Li et al., 2005; Luo, Springer, & Takagi, 2004; Luo, Carman, 
Takagi, & Springer, 2005; Partridge, Liu, Kim, Bowie, & Ginsberg, 2005) 
presumably by altering the length of the transmembrane domains or by disrupting 
the transmembrane helix–helix packing interface that maintains the integrin in an 
inactive state. In fact, platelet activation can be induced by the addition of a 
peptide corresponding to the αIIb transmembrane domain that presumably 
disrupts the inactive transmembrane heterodimer (Yin et al., 2006). Consistent 
with this, Litvinov et al. (Litvinov et al., 2006) recently demonstrated that 
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mutations within the transmembrane helix domain were sufficient to induce 
αIIbβ3 activation by using an interesting laser tweezer-based spectroscopy 
technique to compare the fibrinogen-binding strength of individual activated 
wildtype αIIbβ3 molecules to αIIbβ3 molecules containing transmembrane helix 
mutations. 
 Additional insight into integrin function has recently been gained from 
reports of high-resolution structures of the integrin extracellular domains. Crystal 
structures of αVβ3 (Xiong et al., 2001), αIIbβ3 (Xiao, Takagi, Coller, Wang, & 
Springer, 2004) and single-particle electron microscopy studies of α5β1 (Takagi, 
Strokovich, Springer, & Walz, 2003) reveal a bent or closed conformation in the 
absence of ligand binding, which has been suggested to represent an inactive 
integrin state. While large-scale shifts to a more open conformation have been 
associated with ligand binding to αIIbβ3 (Xiao et al., 2004) and α5β1 (Takagi et 
al., 2003), the subsequent structure of αVβ3 in complex with a ligand-mimetic 
peptide demonstrated minor structural rearrangements in the αV subunit relative 
to the β3 subunit (Xiong et al., 2002). Recently, the crystal structure of αVβ3 in 
the bent conformation was shown to stably bind fibronectin (Adair et al., 2005), 
suggesting that large global changes are not required for switching to a high-
affinity binding state. While these structures may or may not reflect the true 
nature of intact integrins, they provide important evidence for dynamic molecular 
changes within the integrin that may be involved in regulating integrin 
activation”.(Leisner, Yuan, Denofrio, Liu, & Parise, 2007) 
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1.3.1 Integrin αIIb cytoplasmic domain 
 “Currently, only a few αIIb cytoplasmic tail binding proteins have been 
identified and a number of these proteins bind to the conserved membrane-
proximal KXVGFFRKR motif found in all α subunits. Early studies proposed that 
calreticulin may function in regulating integrin αIIbβ3 in platelets since it was 
found to bind to the conserved KXVGFFKR region within the α3 and α5 
cytoplasmic tails (Rojiani, Finlay, Gray, & Dedhar, 1991) and regulate cell 
adhesion (Leung-Hagesteijn, Milankov, Michalak, Wilkins, & Dedhar, 1994). 
Recently, Reilly et al. (Reilly, Larkin, Devocelle, Fitzgerald, & Moran, 2004) 
revisited this question and were not able to detect calreticulin binding to the αIIb 
tail in platelets under a variety of platelet activation states and experimental 
conditions, suggesting an integrin independent role for calreticulin in platelet 
function. Interestingly, this same group (Larkin et al., 2004) identified a chloride 
channel regulatory protein, ICln, that bound to the KVGFFKR motif in αIIb and 
this interaction functionally regulated platelet activation (Larkin et al., 2004). 
Protein phosphatase 1 (PP1c) was also shown to bind to the αIIb tail via the 
KVGFFKR motif (Vijayan, Liu, Li, & Bray, 2004) and to constitutively co-
immunoprecipitate with αIIbβ3 in resting platelets. Upon thrombin stimulation, 
PP1c was found to dissociate from αIIbβ3, resulting in PP1c activation and 
subsequent dephosphorylation of its substrate, myosin light chain. Recently, 
triosephosphate isomerase (TPI) was identified as an αIIb interacting protein via 
yeast two-hybrid analysis (Liu, Corjay, Feuerstein, & Nambi, 2006). Though the 
authors detected TPI mRNA in human platelets, current data limit TPI function to 
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its involvement in an energy production pathway specific to red blood cells and 
brain cells. Therefore, further studies are necessary to determine a functional 
role for TPI in platelet integrin function” (Leisner et al., 2007) 
  “Since CIB1 binds directly to the αIIb tail, we and others have 
hypothesized that this interaction plays a role in regulating αIIbβ3 function. Many 
early studies of integrin αIIbβ3 have relied on ectopic expression of αIIbβ3 in 
Chinese hamster ovary (CHO) cells or other nucleated cell types that fail to 
activate αIIbβ3 in response to agonist stimulation. Recent studies have utilized 
megakaryocytes, which, like platelets, have the capacity to activate αIIbβ3 in 
response to physiological agonists (Shattil et al., 2001; Shiraga et al., 1999). In 
addition, megakaryocytes are amenable to genetic manipulation, thereby 
providing an extremely useful system to dissect the molecular pathways leading 
to integrin activation. Overexpression of CIB1 in megakaryocytes completely 
inhibits agonist-induced fibrinogen binding, while overexpression of a CIB1 
mutant (CIB1 F173A) that does not bind to the αIIb tail (Barry et al., 2002) fails to 
suppress agonist-induced αIIbβ3 activation. Conversely, depletion of CIB1 by 
RNA interference results in enhanced αIIbβ3 activation in response to agonist 
(Yuan et al., 2006b). These results suggest that the CIB1/αIIb interaction may 
negatively regulate αIIbβ3 activation, which may be important in preventing 
spontaneous or inappropriate activation of αIIbβ3. 
 In contrast to the inhibitory role of CIB1 in agonist-induced αIIbβ3 
activation, Tsuboi (Tsuboi, 2002) proposed that CIB1 activates αIIbβ3. It was 
reported that introduction of a peptide encompassing the C-terminal residues 
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179–188 of CIB1 into platelets inhibited agonist-induced αIIbβ3 activation by 
blocking endogenous CIB1 binding to αIIb. The interpretation of these data, 
however, is questioned by recent findings of Yamniuk et al. (Yamniuk et al., 
2006), who were unable to detect an interaction between the CIB1 peptide 
(residues 180–191 in this study) and a CIB1 mutant lacking these C-terminal 
residues or more importantly between an αIIb tail peptide and the C-terminus of 
CIB1 (residues 96–191). 
 Reports by Naik and Naik (Naik & Naik, 2003b) suggest a role for CIB1 in 
αIIbβ3-mediated outside-in signaling during the process of platelet spreading on 
fibrinogen. Interestingly, they find that CIB1 is required for lamellipodia, but not 
filipodia formation. Furthermore, they also propose that CIB1 regulates platelet 
spreading on fibrinogen by regulating focal adhesion kinase activity (Naik et al., 
2003a)” (Leisner et al., 2007).  
 “Additional studies have further explored the role of CIB1 with regard to 
αIIbβ3 and platelets. An interaction between CIB1 and activated Rac3, but not 
Rac1 or Rac2, stimulated αIIb3-mediated adhesion and spreading of CHO cells 
expressing αIIbβ3 (Haataja, Kaartinen, Groffen, & Heisterkamp, 2002). CIB1 was 
also reported to interact with Wiskott–Aldrich syndrome protein (WASP) and this 
complex has been suggested to promote integrin αIIbβ3 activation and platelet 
aggregation (Tsuboi, Nonoyama, & Ochs, 2006)”. (Leisner et al., 2007) 
 
1.3.2 Integrin β3 cytoplasmic domain 
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  “In contrast to the integrin α subunit cytoplasmic tails, the cytoplasmic 
tails of integrin β subunits are highly conserved and possess defined motifs 
required for integrin function. In particular, the β3 cytoplasmic tail contains two 
well characterized tandem NPXY motifs, which serve as recognition sequences 
for phosphotyrosine binding (PTB) proteins (Calderwood et al., 2003) and sites of 
tyrosine phosphorylation (Phillips, Nannizzi-Alaimo, & Prasad, 2001). The wide 
variety of signaling, regulatory and cytoskeletal proteins interacting with the β3 
cytoplasmic domain serve to link αIIbβ3 to cytoskeletal signaling complexes that 
appear to be important for both inside-out and outside-in signal transduction 
events (reviewed in (Liu, Calderwood, & Ginsberg, 2000)).  (Excerpt from Leisner 
et al., 2007) (Leisner et al., 2007).” 
 “Recently, talin, which binds directly to most β cytoplasmic domains via a 
PTB-like interaction with the conserved β tail NPXY motifs, has been implicated 
as a crucial mediator of integrin activation (reviewed in (Ratnikov et al., 2005)). 
The head domain of talin possesses a band 4.1, Ezrin, Radixin, Moesin 
homology (FERM) domain that is folded into F1, F2 and F3 subdomains 
(Calderwood, 2004), of which F2 and F3 have been shown to interact with the 
membrane proximal residues of the β3 tail (Calderwood et al., 2003). The F3 
domain exhibits a substantially greater binding affinity for the β3 tail relative to F1 
and F2 and the recent crystal structure of the F3 domain in complex with a β3 
membrane proximal peptide (residues 739–750) has identified crucial residues 
important for this interaction (Garcia-Alvarez et al., 2003). Talin is also proposed 
to disrupt the inhibitory salt bridge between the α and β cytoplasmic tails, leading 
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to integrin activation (Ratnikov, Partridge, & Ginsberg, 2005; Tadokoro et al., 
2003). (Leisner et al., 2007).”  
 “Interestingly, an interaction between talin and the αIIb tail has been 
observed (Knezevic, Leisner, & Lam, 1996; Yuan et al., 2006b). Recently, CIB1 
was shown to interfere with talin binding to both an αIIb tail peptide and purified 
αIIbβ3, apparently by competing with talin for the CIB1 binding site on the αIIb 
tail. CIB1 inhibition of talin binding may potentially act as a regulatory mechanism 
in platelets to limit or control the extent of ligand binding to αIIbβ3 (Fig. 1.11).” 
(Leisner et al., 2007).  
 
 
1.4. OVERALL GOAL AND PURPOSE OF STUDY 
 The overall goal of my studies, described in this dissertation, is to 
characterize hemostasis in the Cib1-/- mouse.  I hypothesized, for several 
reasons mentioned above, (i.e. Cib1-/- endothelial cell disfunction during the 
pathologic angiogenesis and earlier acute genetic studies with megakaryocytes), 
that the Cib1-/- mice would have hyper-activable platelets and a pro-coagulant 
phenotype.  Over the next couple chapters, I will present data that support 
several conclusions.  First, the Cib1-/- mouse could be a valuable murine model 
for elucidating the critical threshold of plasma protein levels and better defining 
the balance of physiologic versus pathologic hemostasis.  Second, my research 
has expanded our knowledge of regulatory molecules involved agonist-induced 
integrin αIIbβ3 activation.  My results clearly show a difference in CIB1 regulation 
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of agonist-induced αIIbβ3 activation under acute versus chronic genetic 
manipulation.  Since I did not prove my hypothesis in CIB1-/- mice, there are at 
least two interpretations to my data. On interpretation is that CIB1 does not 
regulate agonist-induced αIIbβ3 activation.  However, another interpretation is 
that compensatory mechanisms developed in the Cib1-/- mice to prevent 
increased agonist-induced activation.  If so, either CIB1 itself in the absence of 
compensation or the potential compensatory mechanisms could provide drug 
targets to control platelet activation. 
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Figure 1.1 CIB1 structural motif and key residues.  EF-hands and the correlating 
helices are diagramed.  Key hydrophobic binding pocket residues are marked in 
grey and calcium binding regions in yellow.   Loop regions are marked with a solid 
green line and disordered regions as marked by dotted green lines.  Diagram was 
based on sequence alignment from Gentry et al. 2005. 
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Figure 1.2 Evolution of CIB proteins.  CIB family proteins can be identified through 
evolution as far back as Caenorhabditis via homology searches.  Only a single 
ancestral CIB protein existed until the evolution of vertebrates.  At this point in time, 
the CIB gene duplicated, leading to the existence of the current CIB2 and CIB3.   
CIB2 is the most homologous to ancestral CIB.  CIB1 also evolved during the 
evolution of vertebrates.  Only CIBs1-3 were in existence until mammalian evolution 
when the sequence CIB4 can be identified.        
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Figure 1.3 Homology of critical residues in CIB1 involved in binding.  (A) 
Residues important in the CIB1 hydrophobic binding pocket are listed and the 
corresponding amino acids of CIB2, CIB3 and CIB4 determined by sequence 
alignment (Gentry et al. 2005).  Amino acids with the same or similar chemical 
properties are highlighted in yellow.  (B) The critical residues involved in the 
CIB1/αIIb binding as identified by Barry et al. 2002.  The high level of homolgous 
residues implies that CIBs 2-4 could potentially bind αIIb.  The residues with different 
chemical properties allow variations in binding affinity and specificity between CIBs 
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Myristolyation 
EF-hand 
Calcium binding 
Figure 1.4 Potential EF-hands and myristoylation in CIBs1-4.  EF-hands 
predicted by the Prosite protein motif database (www.expasy.ch/prosite/) and 
drawn in MyDomains Image Creator (www.expasy.ch/prosite/).  All CIB proteins 
have at least 2 EF-hands that bind Ca2+.  An N-terminal myristoylation sequence 
is predicted for CIBs 1-3.  Other EF-hands may exist in CIBs 2-4 but the protein 
sequence could be too degenerate for the stringency used by the program. 
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Figure 1.5 Overall EF-hand geometry and hydrophobic pocket of CIB1.  (A) 
Ribbon diagram of the overall fold of CIB1 showing the positions of the high affinity 
Ca2_ ions (gold spheres) bound to EF-hands 3 and 4. Regions are color-coded: N-
terminal region and EF1 are blue, EF2 is yellow, EF3 is red, EF4 is green, and the 
C-terminal helix is purple. Helices as well as the termini are labeled; a dotted line 
indicates the disordered loop between helices H7 and H8.  (B) Coordinates for CIB1 
(PDB code 1XO5) were read by the program SYBYL version 6.9.1(www.tripos.com), 
hydrogens were added, and MOLCAD molecular surfaces were generated and 
colored to represent the spectrum of hydrophobic potential (red, highly hydrophobic; 
blue, highly hydrophilic). The orientation of CIB1 in this molecular surface 
representation is very similar to that in (A). Reprinted from Gentry et al 2005, with 
permission from the Journal of Biological Chemistry 280(9), 8407-8415, 2005. 
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Figure 1.6 Model of CIB1 C-terminal displacement by αIIb.  (A) The C-terminus 
of unbound CIB1 partially blocks the hydrophobic binding pocket.  Upon binding to 
the cytoplasmic tail of the αIIb integrin subunit the C-terminal tail is displaced.  This 
exposes more hydrophobic residues at the protein surface and increases pocket 
depth.  The C-terminal tail likely acts as a screening mechanism to prevent non-
specific interactions.  Adapted from Yamniuk et al. 2006 (Yamniuk, Ishida, & Vogel, 
2006).  (B) Sequence in αIIb critical for CIB1 binding proposed by Barry et al. 2002 
(Barry et al., 2002). 
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Figure 1.7 Diagram of physiologic hemostasis and pathological thrombus 
formation.  (A) Upon vessel injury, the extracellular matrix proteins are exposed.  
This creates a highly adhesive surface that attracts platelets circulating in the blood 
stream.  Platelets will form transient attachments initially and roll along the 
endothelium.  This process promotes platelet activation.  Activated platelets will 
release their own signaling molecules and recruit more platelets to the area.  Soluble 
plasma proteins act as a bridge to allow platelet aggregation.  Platelets continue to 
aggregate until a stable thrombus is formed, preventing blood loss and initiating 
wound repair.  (B) If spontaneous platelet activation occurs or a clot cannot retract 
and dissolve, a thrombus can occlude a blood vessel inducing hypoxia.  Thrombi 
can also embolize and block smaller downstream blood vessels.  Cholesterol 
buildup and atherosclerotic plaque rupture often create a pro-thrombotic and 
inflammatory environment that promotes thrombus formation and contributes to 
cardiovascular disease. 
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Figure 1.8 Megakaryocyte differentiation and platelet production. (A) 
Megakaryocyte differentiation and platelet production initiate when hematopoietic 
stem cells commit to the myeloid progenitor lineage.  Differentiation continues 
through the megakaryocyte burst forming unit (BFU-MK) stage to megakaryocyte 
colony forming unit (CFU-MK) stage until the fully committed megakaryoblast 
stage.  Afterward, cells stop dividing, become endomitotic and increase their 
nuclear and cytoplasmic volume and ploidy.  Cells continue to grow in size until 
they become fully mature megakaryocytes.  Megakaryocytes extend arm-like 
projections containing proplatelets, which eventually release to form the budding 
platelets. Reprinted from Liu et al 2007, with permission from Current Topics in 
Developmental Biology Vol 80, 2007. (Liu et al., 2007) 
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Figure 1.9 Effect of H-Ras on integrin activation.  (A) Studies by Ginsberg 
and colleagues of integrin in CHO cell using a constitutively active H-Ras 
indicate that H-Ras suppressed integrin activation (Hughes et al., 1997, 2002).  
The signaling pathways involved in H-Ras -dependent suppression were 
determined to be both MEK/Erk dependent and independent.  (B) The bone 
marrow-derived megakaryocyte system was used in our lab to determine the 
role of H-Ras on endogenous integrin activation. Reprinted from Liu et al 
2007, with permission from Current Topics in Developmental Biology Vol 80, 
2007. (Liu et al., 2007) 
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Figure 1.10 Effect of H-Ras on agonist-induced αIIbβ3 activation.  Bone 
marrow-derived megakaryocytes were cultured as described in figure 2 and 
transduced with retrovirus to overexpress the constitutively active H-Ras mutant, 
H-Ras12V, or empty vector.  Megakaryocytes were stimulated with 100 µM ADP, 
10 mM PAR4 peptide or 1 µM PMA in the presence of fluorescently-labeled 
fibrinogen and analyzed by flow cytometry to assess αIIbβ3 activation as 
measured by fibrinogen binding.  Data are presented as the fold increase of 
mean fluorescence over basal binding.  Basal binding is defined as fibrinogen 
binding to unstimulated megakaryocytes. The results indicate no apparent 
inhibition of αIIbβ3 activation by activated H-Ras.  Reprinted from Liu et al 2007, 
with permission from Current Topics in Developmental Biology Vol 80, 2007. (Liu 
et al., 2007) 
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Figure 1.11 Model of CIB1/talin regulation of integrin αIIbβ3 activation. (A) 
In resting platelets, integrin αIIbβ3 exists in an inactive conformation, unbound 
to talin. A portion of CIB1 is localized at the platelet plasma membrane by a 
myristoyl modification of an N-terminal glycine.  (B) Upon agonist stimulation, 
talin binds αIIbβ3 and induces a conformational change within the cytoplasmic 
face leading to integrin activation and ligand binding.  (C) Agonist stimulation 
may also increase the level of CIB1 localization to the plasma membrane and 
enhance CIB1 binding to the αIIb cytoplasmic tail. The CIB1–αIIb interaction is 
thought to interfere with talin-integrin binding thereby attenuating full αIIbβ3 
activation and ligand occupancy. Reprinted from Leisner et al 2007, with 
permission from Current Opinions in Hemotology 14(3), 2007. (Leisner, Yuan, 
Denofrio, Liu, & Parise, 2007) 
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2.1  INTRODUCTION 
 Blood coagulation and thrombus formation are complex processes essential 
to vessel integrity and the prevention of blood loss.   Platelets and endothelial cells 
release both pro- and anti-thrombogenic and –angiogenic factors upon activation.  
The hemostatic molecules released into the plasma mediate adhesive interactions 
among the surrounding environment.  Many plasma proteins have multiple functional 
roles in hemostasis and this physiologic process is carefully balanced by tightly 
controlled release of these molecules.   
 von Willebrand factor (vWF) is a hemostatic protein involved in platelet 
adhesion to the extracellular matrix (ECM), platelet aggregation, thrombus formation, 
and stabilization of coagulation factor VIII.  Mutations in the vWF gene can result in 
mild to severe bleeding disorders.  In fact, von Willebrand disease is the most 
commonly inherited bleeding disorder (Denis et al., 1998).  von Willebrand factor is a 
large protein with a molecular mass 250 kDa that multimerizes to greater than 
20,000 kDa (Ruggeri, 2000).  von Willebrand factor has several binding domains that 
allow binding to collagen, the β3 integrin subunit, glycoprotein (GP) 1bα, coagulation 
factor VIII and heparin.  von Willebrand factor is stored in both α-granules in 
platelets and Weibel-Palade bodies in endothelial cells (Matsushita et al., 2005; 
Ruggeri, 2003b; Wagner, Olmsted, & Marder, 1982; Wagner, 1990; Wagner, 1993) 
and is synthesized only in endothelial cells and platelet precursors, megakaryocytes 
(van Mourik, Romani, & Voorberg, 2002).  Endothelial cells constitutively secrete 
nascent vWF molecules but store more biologically active ultra-large vWF multimers 
in Weibel-Palade bodies (Ruggeri, 1999; Handin & Wagner, 1989).  This is thought 
 56
to be a control mechanism to restrict the highly adhesive and thrombogenic vWF 
multimers to areas of vessel damage (Ruggeri, 2003a).   Ultra-large vWF can be 
observed transiently in normal plasma after endothelial cell stimulation and 
degranulation (Ruggeri, Mannucci, Lombardi, Federici, & Zimmerman, 1982); 
however, these circulating multimers are quickly cleaved by metalloproteinase 
ADAMTS13 (Fujikawa, Suzuki, McMullen, & Chung, 2001; Gerritsen, Robles, 
Lammle, & Furlan, 2001).  von Willebrand factor stored in platelets is pre-
synthesized by megakaryocytes (Jenkins & O'Donnell, 2006).  Plasma vWF is 
proposed to originate mainly from endothelial cells (Bowie et al., 1986) since only 
endothelial cells can constitutively secrete vWF, although platelets also contribute to 
the vWF composition. 
  Another hemostatic protein stored only in platelet α-granules and endothelial 
cell Weibel-Palade bodies is P-selectin (McEver, 2001).  P-selectin is expressed on 
the surface of these cells upon cellular activation.  Once exposed on the membrane 
surface, P-selectin promotes leukocyte and platelet adhesion and rolling along the 
endothelium by binding its ligand PSGL-1 (Dole, Bergmeier, Mitchell, Eichenberger, 
& Wagner, 2005; Frenette et al., 2000; Johnson et al., 1995; Mayadas, Johnson, 
Rayburn, Hynes, & Wagner, 1993; Frenette & Wagner, 1997).  The soluble form of 
P-selectin circulating in plasma results from proteolytic cleavage of the extracellular 
domain and is still fully functional and capable of binding PSGL-1 (Dunlop et al., 
1992; Mehta, Patel, Laue, Erickson, & McEver, 1997).  Soluble P-selectin in human 
plasma can also be produced from an alternatively spliced variant of P-selectin that 
lacks the transmembrane domain (Ishiwata et al., 1994).  A high level of soluble P-
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selectin is often associated with a pro-coagulant state, (Andre, Hartwell, 
Hrachovinova, Saffaripour, & Wagner, 2000; Ikeda et al., 1994; Blann, Faragher, & 
McCollum, 1997; Galkina & Ley, 2006) and thrombotic consumptive disorders such 
as disseminated intravascular coagulation and thrombotic thrombocytopenic purpura 
(Chong et al., 1994; Katayama et al., 1993). 
 CIB1 is a widely expressed protein that binds to platelet integrin αIIb subunit 
of the αIIbβ3 complex (Leisner, Yuan, Denofrio, Liu, & Parise, 2007) and interacts 
with several other proteins including presenilin 2 (Stabler, Ostrowski, Janicki, & 
Monteiro, 1999) and polo-like kinases Fnk and Snk (Kauselmann et al., 1999). CIB1 
is required for PAK1 adhesion-induced activation and the loss of CIB1 leads to 
decreased cell migration (Leisner, Liu, Jaffer, Chernoff, & Parise, 2005).  Studies of 
the Cib1-/- mouse demonstrated that CIB1 plays an important role in angiogenesis 
(Zayed et al., 2007).  Cib1-/- endothelial cells have decreased PAK1 activation, 
ERK1/2 activation and matrix metalloproteinase 2 expression and the Cib1-/- mice 
have decreased pathologic angiogenesis compared to Cib1+/+ mice (Zayed et al., 
2007).  Interestingly, male Cib1-/- mice are sterile as the complete loss of CIB1 
disrupts the haploid stage of spermatogenesis (Yuan et al., 2006).  Since CIB1 
inhibits activation of αIIbβ3 in murine megakaryocytes  and is required for outside in 
signaling (Naik & Naik, 2003) we investigated the hemostatic phenotype of Cib1-/- 
mice and found that both vWF and sP-selectin were significantly increased in the 
Cib1-/- plasma, while whole animal studies demonstrated normal thrombus formation 
and stability in Cib1-/-  mice.   
 
 58
 
2.2   METHODS 
2.2.1 Generation of Cib1-/- mice  
 Generation of Cib1-/- mice was previously described by Yuan et al. (Yuan et 
al., 2006).  Briefly, Genomic Cib1 DNA (all of exon 4 and most of exon 5) was 
replaced with the reversed neomycin gene (Yuan et al., 2006).  All experiments 
performed with mice were in accordance with national guidelines and regulations 
and were approved by the UNC Institutional Animal Care and Use Committee 
(IACUC).   Mice used in the experiments were backcrossed 10 generations onto a 
C57BL6 background. 
 
2.2.2 Platelet isolation 
 Mice were euthanized by CO2.  Blood  was drawn by cardiac puncture into an 
Eppendorf tube containing saline and ACD (85mM sodium citrate, 111 mM glucose 
and 71.4 citric acid)with 0.1 µM PGE1 (Sigma).  To separate blood cells, whole blood 
was centrifuged for 10 min at 250 x g and platelet rich plasma (PRP) was removed.  
Remaining blood was washed, centrifuged and PRP collected.   PRP was pooled 
and centrifuged at 400 x g for 15 min.  Platelet poor plasma was discarded and the 
platelet pellet was resuspended in warmed (37°C) CGS buffer (13mM sodium 
citrate, 30mM glucose and 120mM NaCl) containing 10 U/ml ayprase (Sigma).  
Resuspended platelets were incubated at 37°C for 20 min before being centrifuged 
at 500 x g for 15 min.  The platelet pellet was resuspended in modified HEPES-
Tyrodes buffer (12 mM NaHCO3, 138 mM NaCl, 5.5 mM glucose, 2.9 mM KCl, 
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10mM HEPES containing 0.1% BSA, 1mM CaCl2, 1mM MgCl2 at pH 7.4).  Platelets 
were left to rest 1 h at room temperature (RT) before assaying. 
 
2.2.3 Whole blood analysis   
 Whole blood was drawn into EDTA.  Samples were analyzed by the Animal 
Clinical Chemistry and Gene Expression Laboratory at UNC Chapel Hill with the 
HESKA CBC Hematology System. 
 
2.2.4 Luminex analysis   
 Blood was drawn into Eppendorf tubes containing EDTA and centrifuged at 
2000 x g for 20 min.  Plasma was separated into a new Eppendorf tube and 0.1 µM 
PGE1 was added.  To remove remaining platelets, the plasma was centrifuged at 
1000 x g for 10 min, plasma collected and PGE1 added.  Platelet poor plasma (PPP) 
was centrifuged for 20 min at 2000 x g to remove contaminating microparticles.  
Protease inhibitor cocktail III (Calbiochem) was added and PPP was aliquoted and 
stored at -80°C until use.  Plasma samples were analyzed via Luminex by Rules-
Based Medicine Inc in Austin, Texas. 
 
2.2.5 Plasma protein ELISA   
 Plasma was isolated as above.  Soluble P-selectin concentration was 
measured by ELISA (R&D Systems) following manufacture’s protocol with plasma 
diluted 1:50 in assay buffer.  For the vWF ELISA, 10 µg/well of anti-human vWF 
antibody (DAKO) was incubated at 4°C overnight in Immunex 96-well plates 
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(DYNEX).  The wells were washed three times with PBS.  To block non-specific 
binding, 3% BSA in PBS was added and incubated for 1.5 h at RT.  Wells were 
washed three times with PBS and plasma diluted 1:50 in PBS was added.  Samples 
were incubated for 2 h at RT, washed three times and horseradish peroxidase-
conjugated rabbit anti-human vWF antibody (DAKO) was added at a 1:1000 dilution.  
Antibody was incubated for 1 h at RT before the final three washes.  Chromogenic 
SigmaFAST OPD tablets (Sigma) were used to detect protein binding.  After 15 min 
the color reaction was stopped and O.D. values were read by a Medical Devices 
SpectraMax Plus plate reader at 490 nm.  Graphed O.D. values were normalized per 
experiment by averaging the Cib1+/+ values. 
 
2.2.6 Flow cytometry  
 P-selectin expressed on the platelet surface was measured by flow cytometry 
using a FITC-labeled P-selectin antibody (EMFRET, Germany).  Whole blood 
samples were prepared as described by manufacture’s instructions.  P-selectin 
expression was induced by activation with 100 µM ADP or 0.25 mM PAR4 peptide 
(thrombin receptor activating peptide, AYPGKF, synthesized at the University of 
North Carolina Protein Synthesis Core).  After a 15 min incubation with the antibody, 
samples were diluted with Tyrodes-HEPES and analyzed on a BD FACSCanto flow 
cytometer (BD Biosciences) at a low flow rate.  Mean fluorescence values were 
normalized by agonist stimulated divided by unstimulated. 
 
2.2.7 Western blot analysis 
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 Washed platelets or endothelial cells were lysed in modified CHAPS buffer 
(20 mM HEPES, pH 7.4, 0.15 M NaCl, 10 mM CHAPS, 50 mM NaF, 10 mM β-
glycerophosphate, 1 mM of CaCl2 and MgCl2 and Protease Inhibitors Cocktail Set III 
on ice for 30 min.  Lysates were collected after a 10 min centrifugation.  Protein 
concentration was quantified by the BCA protein assay (Pierce).  Protein samples 
were separated by SDS-PAGE, transferred to a PVDF membrane and subjected to 
Western blotting.  Antibodies against mouse P-selectin and GAPDH were from 
Santa Cruz Biotechnology.  Protein expression was quantified via densitometry with 
software Quantity One (BioRad Fluor-S Multimager) and adjusted using GAPDH as 
loading control. 
 
2.2.8 Endothelial cell culture 
 Endothelial cells were isolated and cultured as described (Zayed et al., 2007).  
Cell lysates were prepared as described above.   
 
2.2.9 Carotid artery thrombosis   
 Adult mice (24-34 g) were anesthetized with isoflurane and maintained under 
inhaled anesthesia at a temperature of 36-37.5°C.  The carotid artery was exposed 
and rinsed with saline.  To measure baseline flow rate, a Doppler flow probe 
(#0.5VB307, Transonic Systems Inc) connected to a flow meter (T106, Transonic 
Systems Inc) was placed on the blood vessel and both were covered with a 
lubricating jelly.  After baseline was determined, the artery was rinsed with saline 
and a 1 x 2 mm piece of Whatman paper saturated with 20% ferric chloride was 
 62
placed on the vessel.  After 2 min, the filter paper was removed from the artery and 
replaced with lubricating jelly.  Blood flow was measured until the vessel occluded.  
 
2.2.10 Bleeding time assay   
 Mice were anesthetized with isoflurane and given an I.P. injection of 10 µl/g 
mouse of ketamine hydrochloride (75µg/kg).  Mouse tails were cut at 4mm from the 
tip and placed into PBS warmed to 37°C.  Time was recorded until the stream of 
blood fully stopped.  Mouse tails were cauterized after 15 min if bleeding did not 
stop.    
 
2.2.11 Statistical analysis 
 All values are presented as the mean plus or minus standard error of the 
mean.  A t-test was used to evaluate statistical significance.  P values less than 0.05 
were considered statistically significant.  
 
 
2.3  RESULTS 
2.3.1 Plasma protein analysis 
 Plasma proteins come from a variety of cellular sources.  The concentration 
of proteins in plasma can be affected by changes in gene expression and protein 
synthesis or changes in exocytosis of storage granules.  We asked whether the loss 
of CIB1 affects granule release, by altering platelet or endothelial cell activation and 
subsequently altering plasma protein levels.  We used Luminex technology to 
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perform a general plasma protein analysis (Table 1).  Of the initial 67 proteins 
screened, vWF concentration displayed the greatest difference between Cib1+/+ and 
Cib1-/- plasma, with a 1.5 fold increase of vWF in Cib1-/- plasma.  We confirmed the 
Luminex results by a vWF ELISA (Fig. 1A).  
 von Willebrand factor is released into plasma from intercellular granules of 
endothelial cells and platelets.  We next determined if soluble P-selectin, a protein 
not in our initial screen, was also increased in Cib1-/- plasma, as they share cellular 
locations.  We measured soluble P-selectin (sP-selectin) concentration by an ELISA.  
We found that Cib1-/- mice also have an increased concentration of sP-selectin in 
their plasma, like vWF, compared to Cib1+/+ mice (Fig. 1B).   
 
2.3.2 Whole blood analysis 
 Since there was an increase in plasma P-selectin and vWF in Cib1-/- mice, we 
examined hemostasis in the Cib1-/- mice on a macroscopic level.   A complete blood 
cell count was preformed on whole blood samples and demonstrated there were no 
significant differences between the two genotypes (Table 2).  Therefore changes in 
plasma protein levels were not due to variations in blood cell number or size.   
 We next used flow cytometry to investigate the activity of platelets in whole 
blood.  By measuring platelet integrin αIIbβ3 activation with an activation specific 
antibody, we determined that basal activation (i.e. the activation of resting platelets) 
in Cib1+/+ and Cib1-/- platelets are similar (Fig. 2A).  Furthermore, platelet activation 
by agonists ADP or PAR4 induced integrin αIIbβ3 activation to the same degree in 
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both Cib1+/+ and Cib1-/- platelets.  Therefore, platelets circulating in the blood of the 
Cib1-/- mice are not more activated than those in the Cib1+/+ mice. 
 
2.3.3 In vivo experiments 
 We then employed whole animal models to determine the response of Cib1-/- 
mice to blood vessel injury, since altered plasma proteins could affect this response.  
A bleeding time assay measures the time necessary for bleeding to stop after the 
removal of a small portion of the mouse’s tail (Subramaniam et al., 1996).  We found 
that the average bleeding time for Cib1-/- mice tended to be prolonged to that of 
Cib1+/+ mice; however, the time difference was not statistically significant (Fig. 2B).  
The ferric chloride injury model is frequently used for assessing in vivo responses to 
injury to the blood vessel endothelium (Denis & Wagner, 2007).  Ferric chloride 
causes tissue damage by iron- mediated chemical oxidation, resulting in separation 
of endothelial cell junctions  and exposure of type I collagen (Furie & Furie, 2005; 
Kurz, Main, & Sandusky, 1990).  To determine the role of CIB1 in thrombus 
formation upon vascular injury, ferric chloride was placed on the carotid artery to 
expose the underlying ECM (Kurz et al., 1990).  Time to full vessel occlusion by a 
stable thrombus was similar between the Cib1+/+ and Cib1-/- mice (Fig. 2C).  Thus 
Cib1-/- mice exhibit no differences in thrombus formation or stability leading to vessel 
occlusion and blood clotting in vivo as measured by these assays.   
 
2.3.4 Protein expression of vWF and P-selectin in platelets and endothelial 
cells 
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 To identify the cellular source of the increased plasma vWF and sP-selectin, 
we analyzed lysates of platelets and cultured endothelial cells isolated from Cib1+/+ 
and Cib1-/- mice.  von Willebrand factor expression in platelet lysate was determined 
by ELISA and Western blotting.  There was no distinguishable difference in vWF 
expression between platelets from Cib1+/+ and Cib1-/- mice (Fig. 3).  An ELISA (Fig. 
4A) and Western blotting (Fig. 4B) for P-selectin expression were also preformed 
with platelet lysates from the Cib1+/+ and Cib1-/- mice.  Again there was no 
detectable difference in P-selectin level in the platelets from the two genotypes.  We 
also analyzed endothelial cell lysates for P-selectin expression by Western blotting 
and did not see differences in protein expression between the Cib1+/+ and Cib1-/- 
samples (Fig. 4C).   
Platelet activation leads to exposure of P-selectin on the platelet surface; 
therefore we used flow cytometry to examine any potential changes in P-selectin 
exposure.  We found similar surface expression levels of P-selectin on resting 
platelets from Cib1+/+ mice and the Cib1-/- mice, and on platelets activated by 0.25 
mM PAR4 or 100 µM ADP (Fig. 4D).  P-selectin surface expression and agonist-
induced α-granule release are not affected by the loss of CIB1.  These results imply 
that it is unlikely that Cib1-/- platelets have a higher concentration of P-selectin stored 
in their α-granules or that the Cib1-/- platelets release the constituents of their α-
granules more readily than Cib1+/+ platelets.   
   
 
2.4  DISCUSSION 
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 In this study we investigated hemostasis in the Cib1-/- mouse.  Plasma 
analysis showed significant differences between Cib1-/- and Cib1+/+ mice by Luminex 
analysis.  Most interesting was the increase of vWF in the plasma of the Cib1-/- mice.  
To validate the results of our Luminex analysis, we verified that vWF concentration is 
increased in the plasma of Cib1-/- by our ELISA.  VWF is stored in platelet α-
granules and endothelial cell Weibel-Palade bodies.  Since P-selectin is also stored 
in same subcellular locations, we asked if sP-selectin concentration in the plasma 
was also increased, as it was not part of our initial Luminex screen.  Using an 
ELISA, we determined that Cib1-/- mice have an increased concentration of sP-
selectin in their plasma than Cib1+/+ mice.    
We then asked if the increased plasma concentration of these two pro-
coagulant proteins (Andre et al., 2000; Hartwell et al., 1998; Ruggeri, 2003b) caused 
increased thrombotic tendencies in the Cib1-/- mouse.  However, platelets in whole 
blood from Cib1+/+ and Cib1-/- mice displayed comparable basal αIIbβ3 binding and 
responded to agonists PAR4 and ADP stimulation similarly, when measured by an 
activation specific antibody binding to integrin αIIbβ3.  This implies that Cib1-/- 
platelets in whole blood are not pre-activated by molecules found in their blood 
plasma.  We then used whole animal models to obtain a global picture of in vivo 
hemostasis in the Cib1+/+and Cib1-/- mice.  Both the bleeding time assay and the 
carotid artery occlusion model showed no statistically significant difference between 
these two genotypes.  Therefore, we can conclude that thrombus formation and 
stability are normal in Cib1-/- mice.  Interestingly, bleeding times for both the vWF-/- 
and P-selectin-/- mouse are prolonged (Denis et al., 1998; Subramaniam et al., 
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1996).  Mice deficient in vWF also have a prolonged time until full blood vessel 
occlusion in the ferric chloride injury model (Denis et al., 1998), while in a similar 
thrombosis model using a laser to initiate vessel injury, P-selectin-/- mice have 
decreased thrombus stability (Falati et al., 2004). Since deficiency in vWF or P-
selectin leads to defects in thrombus formation and stability, it is surprising that mice 
that have increased plasma concentrations of both proteins, have no thrombotic 
effect as measured by these assays.  This implies that there are critical thresholds 
for both proteins that above or below will result in hemostatic defects. 
 To identify the source of sP-selectin and vWF in plasma, we analyzed 
platelets and endothelial cells from the Cib1-/- mice. Platelet lysates from Cib1+/+ and 
Cib1-/- mice displayed no change in vWF or P-selectin concentration by ELISA or 
Western blot.   Surface expression of P-selectin on platelets from Cib1-/- and Cib1+/+ 
mice was similar at a resting state and upon agonist stimulation.  This implies that 
the Cib1-/- platelets do not have increased P-selectin stored or released from their α-
granules.   
 The primary endothelial cells used in this report were isolated and cultured 
from Cib1+/+ and Cib1-/- mice.  Therefore, there is the possibility that these cells may 
have different protein expression when removed from the mouse and grown in 
culture conditions.  For this reason, we cannot exclude the possibility that endothelial 
cells in vivo are the source of the increase in plasma sP-selectin and vWF.  Previous 
studies demonstrate that the loss of CIB1 affects cultured endothelial cell migration, 
proliferation and tubule formation (Zayed et al., 2007).  These studies also 
demonstrated that CIB1 is involved in pathological angiogenesis in vivo (Zayed et 
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al., 2007).  A defect in endothelial cell function upon the loss of CIB1 supports the 
hypothesis that these cells may also have difficulty regulating P-selectin and vWF 
levels.  Furthermore, Cib1-/- platelets do not display any significant differences from 
Cib1+/+ platelets (DeNofrio et al. submitted).  
 Many studies have demonstrated a strong functional interaction between P-
selectin and vWF (Denis, Andre, Saffaripour, & Wagner, 2001a; Dole et al., 2005) 
and both of these proteins are involved in atherosclerosis (Denis et al., 2001a; Dole 
et al., 2005; Ley, 2003; Mendolicchio & Ruggeri, 2005; Andre et al., 2000; Guray et 
al., 2004).  Elevated sP-selectin and vWF are often considered predictors of 
cardiovascular events (Galkina et al., 2006; Montalescot et al., 1998; Varughese et 
al., 2007; Blann et al., 1997; Blann & Lip, 1997).  Interestingly, other procogaulant 
proteins involved in  cardiovascular events such as C-reactive protein (Danenberg et 
al., 2007) and tissue factor (Mackman, 2004) were found to have similar levels in 
Cib1+/+ and Cib1-/- plasma (Table1).  The administration of interleukin-11 has been 
shown to increase plasma vWF levels in human clinical studies (Tepler et al., 1996) 
and both vWF+/+ and vWF+/- mice (Denis et al., 2001b).  Level of endogenous 
interleukin-11 is unchanged in the plasma from Cib1-/- mice.  Though the mechanism 
promoting the increase of plasma P-selectin and vWF remains unclear, the Cib1-/- 
mouse can potentially be used to further our understanding of the physiologic roles 
of plasma proteins that are involved in hemostasis.  
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Table 2.1 Luminex analysis of plasma from Cib1+/+ and Cib1-/- mice. Values in 
upper boxes are the fold difference of Cib1-/- protein concentration over the Cib1+/+ 
protein concentration.  Lower panels represent proteins that were screened 
demonstrated no significant difference in concentration between plasma from Cib1+/+ 
and Cib1-/- mice.    
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Table 2.2 Comprehensive blood cell analysis.  The concentration of each blood 
cell type was determined along with other important parameters.  The blood cell 
analysis did not display any significant differences between the Cib1+/+ and Cib1-/-
whole blood. 
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Figure 2.1 Plasma from Cib1-/- mice has increased levels of von Willebrand 
Factor and soluble P-selectin compared to Cib1+/+ plasma.  (A)  Plasma samples 
analyzed by ELISA demonstrate that plasma from Cib1-/- has higher levels of von 
Willebrand factor than plasma from Cib1+/+ as determined by ELISA.  Data was 
normalized by setting the mean von Willebrand factor O.D. from Cib1+/+ plasma to 1 
(N ≥ 4).  (B) Cib1-/- mice have more soluble P-selectin circulating in their plasma than 
Cib1+/+ mice as measured by ELISA.  Concentrations were determined from known 
mouse soluble P-selectin standards (N = 17). 
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Figure 2.2 Platelet activation and thrombus formation are normal in Cib1-/- 
mice.  (A)  Platelet activation, as measured by integrin αIIbβ3 basal binding and 
agonist-induced activation, demonstrates that platelets from Cib1+/+ and Cib1-/- mice 
are activated similarly.  Integrin activation was determined by flow cytometry to 
detect binding of an αIIbβ3 activation-specific antibody (N = 6).  (B) Bleeding time 
assay was used to measure thrombus formation and stability in Cib1+/+ and Cib1-/- by 
cutting the distal 4 mm portion of the tail and recording clotting time.   Cib1-/- mice 
had mildly prolonged bleeding time but the difference was not statistically significant 
from Cib1+/+ (N ≥ 20).  (C) A carotid artery thrombosis model was also used to detect 
differences in thrombus formation and stability.  Ferric chloride (20%) saturated 
paper was placed on the carotid artery to induce injury.  Time necessary for full 
vessel occlusion was recorded and graphed (N = 8). 
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Figure 2.3 Platelets from Cib1+/+ and Cib1-/- mice have similar levels of von 
Willebrand factor.  Platelet lysates analyzed by a von Willebrand factor ELISA (A) 
or Western blotting (B) demonstrate Cib1+/+ and Cib1-/- platelets have similar levels 
of intracellular von Willebrand Factor.  Y-axis in (A) shows Cib1-/- OD divided the 
mean Cib1+/+ mean O.D..  ERK1 was used as a loading control for the Western blots 
(N = 2 for ELISA experiments).   
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Figure 2.4 P-selectin levels are similar in Cib1+/+ and Cib1-/- platelets and 
endothelial cells.  Soluble P-selectin ELISA (A) and Western blotting (B) of platelet 
lysates demonstrated P-selectin expression is comparable in platelet lysates from 
Cib1+/+ and Cib1-/- mice (N ≥ 2).  Western blots of endothelial cell lysates also 
showed similar levels of P-selectin expression between the two genotypes.  GAPDH 
was used as a loading control for both (B) and (C).  (D) Platelet P-selectin surface 
expression is not affected by the loss of CIB1 as measured by flow cytometry.  P-
selectin was expressed on the platelet surface at similar levels after agonist 
stimulation with 100 µM ADP or 0.25 mM PAR4 peptide) (N ≥ 3). 
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CHAPTER 3 
CHARACTERIZATION OF CIB1 KNOCKOUT PLATELETS: POTENTIAL 
COMPENSATION BY CIB FAMILY MEMBERS 
 
PREFACE 
 The work in this chapter has been submitted to the Journal of Biological 
Chemistry.  This manuscript was authored by Jan DeNofrio, Weiping Yuan, Brenda 
Temple, Holly Gentry and Leslie Parise.  Most of the experiments and writing were 
done by Jan DeNofrio and Dr. Weiping Yuan, who share co-first authorship.  Dr. 
Brenda Temple did the CIB homology prediction model and Dr. Holly Gentry helped 
purify some of the recombinant proteins. 
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3.1  INTRODUCTION 
 Platelets respond to blood vessel injury to prevent further blood loss and 
restore vascular integrity.  They become activated at the site of vascular injury by 
newly exposed extracellular matrix proteins (ECM) and secreted soluble agonists.  
Platelet activation promotes soluble and matrix adhesive protein binding to activated 
surface receptors.  The interaction of platelets with soluble proteins such as 
fibrinogen initiates platelet aggregation, whereas platelet interaction with ECM 
proteins such as collagen allows platelet adhesion.   
 Integrins are heterodimeric adhesion receptors that undergo conformational 
changes upon agonist stimulation, which results in increased ligand affinity.  This 
process is termed inside-out signaling (for review see Parise 1999) (Parise, 1999).  
The most abundant integrin on the platelet surface is αIIbβ3.  Active integrin αIIbβ3 
initiates and propagates the formation of platelet aggregates by binding to 
fibrinogen.  Although fibrinogen is the primary ligand for αIIbβ3, the activated integrin 
also binds fibronectin, von Willebrand factor and vitronectin to support platelet 
adhesion to the extracellular matrix (Kieffer & Phillips, 1990; Phillips, Charo, & 
Scarborough, 1991).  Since uncontrolled activation of integrin αIIbβ3 can cause 
pathologic thrombus formation, precise regulation of the integrin is critical for 
hemostasis (Andrews & Berndt, 2004).   
 CIB1 (CIB, calmyrin, and KIP1) was identified in a yeast-two hybridization 
screen to identify binding partners for the integrin αIIb cytoplasmic tail (Naik, Patel, & 
Parise, 1997).  CIB1 is a widely expressed protein that contains two calcium binding 
and two non-calcium binding EF hands (Gentry et al., 2005; Yamniuk & Vogel, 
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2005).  CIB1 interacts with a number of serine/threonine kinases such as DNA-
dependent protein kinase (Wu & Lieber, 1997), polo-like kinases Fnk and Snk 
(Kauselmann et al., 1999), and PAK1 (Leisner, Liu, Jaffer, Chernoff, & Parise, 2005), 
as well as presenilin 2 (Stabler, Ostrowski, Janicki, & Monteiro, 1999), FAK(Naik & 
Naik, 2003a)  and the InsP3 receptor (White, Yang, Monteiro, & Foskett, 2006).  
Recent in vivo studies demonstrate that CIB1 also plays a role in pathological forms 
of angiogenesis (Zayed et al., 2007) and is essential for spermatogenesis (Yuan et 
al., 2006a).      
 Previously, the function of CIB1 relative to αIIbβ3 was explored by acutely 
overexpressing and knocking down the protein in murine megakaryocytes.  These 
studies implicated CIB1 as a negative regulator of agonist-induced αIIbβ3 activation 
(Yuan et al., 2006b).   In separate studies where CIB1 function was also rapidly 
blocked by use of a CIB1 antibody, it was found that CIB1 is necessary for proper 
spreading on immobilized fibrinogen (Naik & Naik, 2003b).  Taken together these 
studies imply that acute alterations in CIB1 protein, misregulates αIIbβ3 activation. 
 To fully characterize the role of CIB1 in αIIbβ3 activation, we asked if the 
chronic loss of CIB1, via study of a knockout mouse, would result the same 
phenotype as acutely altered CIB1.  While we hypothesized that loss of CIB1 would 
result in increased agonist-induced activation of integrin αIIbβ3, and hyper-
activatable platelets, the Cib1-/- mice (Yuan et al., 2006a)   did not display any overt 
defect in platelet function.  Taken together, these results suggest that either CIB1 
does not regulate the platelet functions tested or that developmental compensation 
has occurred.  Interestingly, mRNA expression for the CIB1 homolog CIB3 is 
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increased in cultured megakaryocytes isolated from the Cib1-/- mice.  These proteins 
may have a redundant or overlapping function in αIIbβ3 regulation and may 
compensate for the lack of CIB1.  To test this, we produced recombinant CIB1, -2 
and -3 and compared their ability to bind to the αIIb cytoplasmic tail. 
  
 
3.2  METHODS 
3.2.1 Mice   
 Generation of Cib1-/- mice was previously described by Yuan et al. (Yuan et 
al., 2006a).  All mouse experiments were performed in accordance with national 
guidelines and regulations and were approved by the UNC Institutional Animal Care 
and Use Committee (IACUC).   Mice used in these experiments were backcrossed 
10 generations to the C57BL6 background.  
  
3.2.2 Platelet isolation   
 Mice were euthanized by CO2.  Blood was drawn by cardiac puncture into an 
Eppendorf tube containing saline and ACD (85 mM sodium citrate, 111 mM glucose 
and 71 mM citric acid) with 0.1 µM PGE1 (Sigma).  To separate blood cells, whole 
blood was centrifuged for 10 min at 250 x g.  Platelet rich plasma (PRP) was 
removed and the remaining blood was washed with ACD/saline/PGE1 solution, 
centrifuged and PRP collected.   PRP was pooled for each mouse and centrifuged at 
400 x g for 15 min.  Platelet poor plasma (PPP) was discarded and the platelet pellet 
resuspended in warmed (37°C) CGS buffer (13 mM sodium citrate, 30 mM glucose 
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and 120 mM NaCl) containing 10 U/ml apyrase (Sigma).  Resuspended platelets 
were incubated at 37°C for 20 min before being centrifuged at 500 x g for 15 min.  
The platelet pellet was resuspended in 0.5 ml modified HEPES-Tyrodes buffer (12 
mM NaHCO3, 138 mM NaCl, 5.5 mM glucose, 2.9 mM KCl, 10mM HEPES 
containing 0.1% BSA, 1mM CaCl2, 1mM MgCl2 at pH 7.4).  Platelets were allowed to 
rest for 1 h at room temperature (RT) before assaying. 
  
3.2.3 Electron Microscopy  
  PRP was isolated as above and centrifuged at 400 x g for 15 min.  PPP was 
removed and the platelet pellet was fixed by the addition of 2% glutaraldehyde in 0.1 
M sodium cacodylate buffer pH 7.4 (all buffers provided by UNC Microscopy 
Services Laboratory).  After 2 h at RT, the glutaraldehyde solution was removed, the 
pellet washed with cacodylate buffer and then fixed in potassium ferrocyanide-
reduced osmium tetroxide for 1 h at RT.  The pellet was dried with ethanol and 
embedded in PolyBed 812 epoxy resin (Polysciences, Inc. PA).  Sections of the 
pellet (70 nm thick) were mounted on copper grids and stained with 4.0% uranyl 
acetate and 0.4% lead citrate.  Sections were observed with a LEO EM 910 
transmission electron microscope (LEO Electron Microscopy, Inc. NY) using an 
accelerating voltage of 80 kV. 
  
3.2.4 Platelet spreading 
 Glass coverslips were coated with 1% BSA (Serologicals Protein Inc) or 100 
µg/ml fibrinogen (Calbiochem).  Platelets were isolated and washed as above and 
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resuspended in Tyrodes-HEPES buffer to 1 x 107 plts/ml.  Precoated coverslips were 
washed twice with Tyrodes-HEPES buffer and 100 µl platelets were added and 
incubated for 1 h at 37°C.  Coverslips were aspirated to remove unattached cells 
and remaining cells were fixed with 1.0% paraformaldehyde for 15 min at RT.  
Coverslips were washed twice and permeablized with 0.2% Triton-PBS for 30 
seconds and washed three times with Tyrodes-HEPES.  For staining, coverslips 
were incubated in the dark with 1:1000 phallodin-488 (Molecular Probes) for 30 min.  
Coverslips were rinsed and adhered to slides with FlouroSave (Calbiochem). 
  
3.2.5 Flow cytometry   
 Washed platelets were incubated with FITC-labeled antibody for 15 min 
(JON/A, glycoprotein (GP) 1b and respective IgG controls, EMFRET, Germany) or 
30 min (αIIb or α2 and respective IgG controls, BD BIOSCIENCE) at RT.   For 
αIIbβ3 activation experiments, agonist (0.1 U thrombin or 10 µM ADP final 
concentrations) was added simultaneously with the antibody.  After incubating, 
samples were diluted with Tyrodes-HEPES and analyzed on a BD FACSCanto flow 
cytometer (BD Biosciences) at a low flow rate.  Surface expression data were 
normalized by dividing the mean fluorescent intensity of the antibody by the IgG 
control intensity.  Activation data were normalized by dividing the agonist stimulated 
mean fluorescence by that of the unstimulated cells. 
 
3.2.6 Aggregation   
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 Platelets were isolated as above and diluted into Tyrodes-HEPES buffer to 
1.5 x 108 plts/ml.   Platelets were aliquoted into aggregation tubes and incubated at 
37° C for 15 min before the addition of agonist, 0.1 mM PAR4 peptide (AYPGKF, 
synthesized at UNC Protein Chemistry Core) or 5 µM ADP.   Traces were recorded 
for 5-6 min in a CHRONO-LOG Corporation Model 700 Aggregometer.  
Aggregometry data were analyzed by Aggrolink8 software (CHRONO-LOG). 
  
3.2.7 Western blot analysis   
 Washed platelets were lysed in modified CHAPS buffer (20 mM HEPES, pH 
7.4, 150 mM NaCl, 10 mM CHAPS, 50 mM NaF, 10 mM β-glycerophosphate, 1:100 
concentration of Protease Inhibitors Cocktail Set III (Calbiochem), 1 mM CaCl2 and 1 
mM MgCl2) on ice for 30 min.  Lysates were collected after a 10 min centrifugation 
and the protein concentration was quantified by the BCA protein assay (Pierce).  
Protein samples were separated by SDS-PAGE, transferred to a PVDF membrane 
and subjected to Western blotting.  A CIB1 chicken polyclonal antibody was used to 
detect mouse CIB1.  The antibody against GAPDH was from Santa Cruz 
Biotechnology.    
  
3.2.8 Primary megakaryocyte culture   
 Murine bone marrow-derived megakaryocytes were cultured as previously 
described (Shiraga et al., 1999).  Briefly, bone marrow cells were flushed and 
isolated from tibias and femurs of mice and cultured for three days in medium 
containing Interleukin (IL)-6, IL-11 and thrombopoietin (PeproTech). 
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3.2.9 Quantitative reverse transcriptase-PCR   
 Megakaryocytes derived from bone marrow stem cells were isolated as 
above.  RNA was isolated with the Qiagen RNA Isolation kit.  Isolated RNA was 
transcribed into cDNA using Applied Biosystems’ High-Capacity Reverse 
Transcription Kit.   Primers for Cib1, Cib2, Cib3, Cib4 and Gapdh were purchased 
from SuperArray.  Sequences were proprietary, reference positions for partial 
product sequence amplified by primers, relative to NCBI RefSeq entry provided by 
SuperArray; Cib1 260-278 (RefSeq Accession# NM_011870), Cib2 590-609 
(RefSeq Accession# NM_019686), Cib3 326-344 (RefSeq Accession# 
XM_356089.4), Cib4 271-291 (RefSeq Accession# XM_131990.3) and Gapdh 962-
983 (RefSeq Accession# NM_008084.2).  SYBR Green PCR Mastermix was also 
from SuperArray and manufacturer’s protocol was followed.  Real time qPCR 
reactions were run on Applied Biosystems Instruments Prism 7900HT Sequence 
Detection System using the standard 1 cycle at 95° C for 10 min and 40 cycles of 
95° C for 15 s then 60° C for 1 min.  Fold change in gene expression was calculated 
using the ∆∆Ct method(Livak & Schmittgen, 2001; Schefe, Lehmann, Buschmann, 
Unger, & Funke-Kaiser, 2006). 
  
3.2.10 Protein purification   
 PCR primers were designed to amplify Cib1-3 mRNAs isolated from murine 
megakaryocytes.  PCR products of Cib1, -2 and -3 were ligated into the pEXP5-
NT/TOPO vector (Invitrogen) and correct sequences were verified.  BL21 bacteria 
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(Stratagene) were transformed with pEXP5-NT/TOPO vectors, grown at 37°C and 
induced with isopropyl β-D-1-thiogalactopyranoside (IPTG) for 4 h at 30°C to 
produce desired proteins.  pEXT5-NT/TOPO calmodulin-like 3 from Invitrogen was 
used as a control.  Bacteria producing CIB1, CIB2 and calmodulin-like 3 were lysed 
by sonication and centrifuged at 10,000 x g for 20 min.  Supernatant was run on an 
FPLC-nickel column to purify the protein.  Since CIB3 was insoluble, the bacteria 
producing CIB3 were lysed and denatured in buffer containing 8 M urea (Sigma), 
100 mM NaH2PO4 (Mallinckrodt) and 10 mM Tris-Cl (Fisher) at pH of 8.0.  Lysate 
was centrifuged to remove cellular debris and Ni-NTA slurry (Qiagen) was added to 
the supernatant and incubated at RT for 1 h with shaking.   The lysate-resin mixture 
was loaded into a column and flow- through was removed.  The column was washed 
twice with buffer containing 8 M urea, 100 mM NaH2PO4 and 10 mM Tris-Cl at pH 
6.3.  Protein was eluted with buffer containing 8 M urea, 100 mM NaH2PO4 and 10 
mM Tris-Cl at pH 5.9.  Eluate was dialyzed into 8 M urea, 200 mM NaCl and 50mM 
Tris pH 8.0 at 4° C. After 4 h, an equal volume of buffer containing 200 mM NaCl 
and 50 mM Tris pH 8.0 with 2 mM dithiothreitol (DTT, ROCHE) was added to dilute 
the urea and left to dialyze overnight.  Buffer was then exchanged with 2 M urea, 
200 mM NaCl, 50 mM Tris pH 8.0 and 2 mM DTT to continue dialyzing and allow 
protein refolding.  This process continued every 8 h until the urea was fully removed.  
The DTT was then dialyzed out with 200 mM NaCl, 50 mM Tris pH 7.5.  The protein 
was then dialyzed into a final buffer containing 20 mM Tris pH 7.5, 300 µM CaCl2 
and 85 mM NaCl. 
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3.2.11 ELISA    
 An αIIb cytoplasmic tail (CT) peptide (sequence LVLAMWKAGFFKRNR 
synthesized by Genscript Corporation) or a scrambled control peptide (sequence 
DKFGRPPKVENEELEDRGEF, synthesized by UNC Protein Chemistry Core 
Facility) was coated on a microtiter plate (NUNC) overnight at 4°C at a concentration 
of 75 µg/ml.  BSA (3%) was used to block non-specific interactions in peptide-coated 
and non-coated wells.  Proteins were diluted in 50 mM HEPES, 150 mM NaCl with 
0.1 mM CaCl2 and MgCl2 pH 7.4 to a range of 0.5 µg/ml to 20 µg/ml and were 
allowed to adhere to the plate for 1 h at RT.  The samples were removed and the 
plate was washed three times with 0.5% TBS-Tween, pH 7.4.  A primary anti-HIS 
antibody was added and incubated for 1 h at RT.   The antibody was removed and 
plate was washed as above.  An anti-rabbit-HRP antibody was then added to the 
microtiter plate for 1 h at RT.  The secondary antibody was removed and the plate 
was washed as above.  Binding was visualized by a color reaction with chromogenic 
substrate OPD Sigma Fast Tablets (Sigma) for 10 min at RT in the dark.  The 
reaction was stopped with 4N H2SO4 and the plate was read at 490 nm in Medical 
Devices SpectraMax Plus plate reader.  For competitive binding assays, 5 µg/ml of 
CIB1, -2 and -3 were incubated with increasing concentrations (1.0-100 µg/ml) of 
soluble αIIb peptide.  Each sample and concentration was performed in triplicate for 
all ELISAs. 
  
3.2.12 CIB homology and model analysis   
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 CIB homologs in the UniProt database (Bairoch et al., 2005) were identified 
using sequence similarity BLAST searches (Altschul & Lipman, 1990) of the human 
CIB1 protein.  We used ClustalX (Chenna et al., 2003) to generate a multiple 
sequence alignment of the three human CIB homologs (CIB1 (Q99828), CIB2 
(O75838), CIB3 (Q96Q77)), and homologs of the fruitfly and worm CIB gene (D. 
melanogaster (Q9W2Q5), D. pseudoobscura (Q28ZR4), C. elegans (Q93640)).  We 
then mapped highly conserved residue positions onto the crystallographic structure 
of human CIB1 (PDB ID 1XO5 (Gentry et al., 2005)). 
 
3.2.13 Statistical analysis   
 All values are presented as the mean ± standard error of the mean (SEM).  A 
t-test was used to evaluate statistical significance.  P values less than 0.05 were 
considered statistically significant.  N ≥ 3 for all experiments. 
 
 
3.3  RESULTS 
3.3.1 Platelet function is normal in Cib1-/- mice   
 We first confirmed that CIB1 was indeed absent in the Cib1-/- platelets by 
Western blotting (Fig. 1A).  The overall morphology of the platelets by transmission 
electron microscopy appeared normal (Fig. 1B); platelet shape and organelles were 
similar in both genotypes.  Flow cytometry with antibodies specific to integrins αIIbβ3 
and α2β1, and glycoprotein (GP) Ib (Fig. 1C) indicated that there were no 
statistically significant differences detected in the expression levels of these three 
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proteins on platelets isolated from the Cib1+/+ and Cib1-/- mice.   These results 
thereby assure that any difference displayed in our αIIbβ3 functional studies was not 
due to a change in surface expression of αIIbβ3.   
 To examine potential differences in αIIbβ3 activation between Cib1+/+ and 
Cib1-/- mice, we measured binding of an activation-specific antibody binding (JON/A) 
to αIIbβ3 integrin in resting or agonist stimulated platelets by flow cytometry (Fig. 
2A).  Basal αIIbβ3 activity in resting platelets was comparable in Cib1-/- and Cib1+/+ 
mice (measured by the binding of unstimulated cells to the JON/A antibody).  We 
also found no significant difference in the ability of Cib1-/- platelets to respond to a 
relatively weak agonist (10 µM ADP), or strong agonist (0. 1 U thrombin) versus 
platelets isolated from Cib1+/+ littermate controls.  Platelets aggregation was also 
used to evaluate αIIbβ3 activation.  We found that Cib1-/- platelets aggregate in a 
similar manner when stimulated by agonist 0.1 mM PAR4 peptide or 10 µM ADP as 
those from  Cib1+/+ mice (Fig. 2B).  These results imply that the absence of CIB1 
does not alter the integrin αIIbβ3 expression and activation in platelets.   
 Acute blockade of CIB1 in platelets inhibits platelet spreading on immobilized 
fibrinogen (Naik et al., 2003b; Naik et al., 2003a).  We therefore tested platelets from 
the Cib1-/- mice to determine the effect of the loss of CIB1 on platelet spreading, but 
found no difference between size and overall cell number of platelets adhered to 
fibrinogen in the presence or absence of ADP (Fig. 3A-C).  Platelet spreading was 
also similar between the two genotypes after PAR4 stimulation, or on collagen in the 
absence or presence of ADP (data not shown).   Therefore, outside-in signaling as 
measured by platelet spreading appears to be normal in the Cib1-/- deficient mice. 
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3.3.2 Cib1 homolog Cib3 is overexpressed in Cib1-/- primary megakaryocytes.  
 Our previous studies involving the acute modulation of CIB1 levels in 
megakaryocytes showed that CIB1 is an endogenous inhibitor of αIIbβ3 activation 
(Yuan et al., 2006b).  Here we tested αIIbβ3 activation in megakaryocytes from the 
Cib1-/- mice to determine whether chronic loss of CIB1 has a similar phenotype to the 
acute megakaryocyte studies (Yuan et al., 2006b). Megakaryocytes differentiated in 
culture from the bone marrow stem cells of Cib1-/- mice bound fibrinogen in a similar 
manner as those from Cib1+/+ mice.  Specifically, both genotypes had similar levels 
of basal fibrinogen binding, and fibrinogen binding upon stimulation with agonist 
PAR4 (Fig. 2C).  Therefore, activation of αIIbβ3 on megakaryocytes from the Cib1-/- 
mice is similar to that of megakaryocytes derived from Cib1+/+ mice.  This result 
models our Cib1-/- and Cib1+/+ platelet data, and are in contrast to results obtained 
with short term direct protein or genetic manipulations (Naik et al., 2003a; Yuan et 
al., 2006b; Naik et al., 2003b; Tsuboi, 2002). 
 Since we did not see a change in αIIbβ3 activation in Cib1-/- mouse platelets 
or megakaryocytes, we considered the possibility of functional compensation by 
other CIB family members, as the chronic loss of CIB1 could alter the expression of 
other genes. Genes of human homologs Cib2, Cib3 and Cib4 have been reported 
(Gentry et al., 2005) and genes of mouse Cib2-4 can be identified in the mouse 
gene database.  Therefore, we examined the expression of these mouse genes 
using real-time qPCR with mRNA derived from cultured murine megakaryocytes.  I 
found increased Cib3 mRNA expression in the Cib1-/- bone marrow derived 
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megakaryocytes while Cib2 message levels remained constant between Cib1+/+ and 
Cib1-/- megakaryocytes (Fig. 3A). Cib4 was excluded from further studies because 
only a very low level of Cib4 cDNA (slightly above background) was detected from 
megakaryocytes and other tissue by reverse transcriptase-PCR and qPCR in either 
genotype (data not shown).   
 Since mRNA from the Cib1-/- megakaryocytes displayed a different 
expression pattern for CIB3 relative to Cib1+/+ megakaryocytes, I further investigated 
the possibility of functional compensation.  We produced and purified the 
recombinant CIB1, -2 and -3 proteins from bacterial cultures to test the binding 
properties of CIB family proteins with integrin αIIb.  It is currently unknown whether 
CIB2 or CIB3 is expressed in platelets.  CIB2 protein expression has been identified 
in HEK cells (Mayhew et al., 2006) but CIB3 protein remains to be examined or 
reported and antibodies that recognize mouse CIB2, -3, or -4 are not currently 
available. Nonetheless, I asked if recombinant murine CIB2 and CIB3 could bind to 
αIIb. We immobilized an αIIb-CT peptide in microtiter wells, added increasing 
concentrations of CIB1, -2, and -3 proteins and measured binding by ELISA (Fig. 
4B).  Interestingly, all three CIB proteins bound to immobilized αIIb-CT peptide.  
However, none of the proteins bound to a scrambled control peptide, implicating a 
specific interaction between these CIB proteins and αIIb (Fig. 4B).  To further ensure 
the specificity of binding of these proteins to the αIIb-CT peptide, I added increasing 
concentrations of soluble αIIb peptide to compete with CIB1 protein binding to 
immobilized peptide.  Addition of this soluble peptide decreased the binding of CIB1, 
-2 or -3 to immobilized peptide (Fig. 4C).  , reaffirming that there is a specific 
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interaction between the αIIb-CT peptide and CIB proteins, whereas the soluble 
scrambled peptide did not interfere with the CIB protein binding to immobilized αIIb 
peptide (data not shown).  These findings demonstrate that CIB2 and CIB3 can bind 
to the cytoplasmic tail of αIIb in vitro and therefore have the potential to compensate 
for the loss of CIB1. 
  
3.3.3 CIB family computer modeling 
 For insight into the potential mechanism of how CIB2 and/or CIB3 might 
compensate for the loss of CIB1 in αIIbβ3 regulation, we performed computer 
modeling studies.  We evaluated CIB family homology by aligning the ancestral CIB 
protein from worm (Caenorhabditis elegans) and fruit fly (Drosophila melanogaster) 
with the human CIB1-3 proteins. Highly conserved residues are represented in 
purple and yellow while non-conserved residues are represented in grey and orange 
(Fig. 5).  The conservation is indicative of potential functionality that existed in the 
CIB ancestor and that has been maintained in the CIB1-3 homologs (purple and 
yellow residues Fig. 5).   
 Residues in CIB1 that are proposed to interact with αIIb based on previous 
studies and on the crystal structure (Barry et al., 2002; Gentry et al., 2005; Naik et 
al., 1997; Shock et al., 1999; Yamniuk et al., 2005; Yamniuk, Ishida, & Vogel, 2006) 
of CIB1 were specifically compared to the corresponding residues in CIB2 and CIB3.  
CIB residues hypothesized to form the hydrophobic binding pocket for the αIIb tail 
are designated by yellow for conserved and orange for non-conserved (Fig 5A).  
Almost all of the residues in the hydrophobic binding pocket are highly conserved 
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between the three human CIB homologs and the worm and fruit fly CIB homolog, 
indicating a potentially shared functional domain. 
 The C-terminus of CIB1 has been proposed to be displaced upon αIIb binding 
(Yamniuk et al., 2006) therefore we also performed a modeling analysis with the C-
terminus of CIB2 and CIB3 removed (Fig. 5B).  The additional residues exposed in 
CIB2 and CIB3 were highly homologous to those exposed in CIB1 upon C-terminal 
deletion (Fig. 5B).  In addition, the length and depth of the hydrophobic binding 
pocket was enlarged similarly between each CIB protein. This suggests that all three 
CIB proteins may use the C-terminus to control binding specificity as proposed by 
Yamniuk et al. 2006 (Yamniuk et al., 2006) for CIB1.  
 
 
3.4 DISCUSSION 
 Activation and regulation of platelet integrin αIIbβ3 has been extensively 
studied since identification of the protein in 1980 (Phillips, Jennings, & Edwards, 
1980; Phillips, 1980), yet the precise mechanism of integrin activation and molecules 
involved in this process are still under investigation.  Several intracellular binding 
partners of the integrin are known to regulate αIIbβ3 activation (Leisner, Yuan, 
Denofrio, Liu, & Parise, 2007).  Interestingly, most of these regulatory proteins bind 
to the β3 cytoplasmic tail and not to αIIb (Leisner et al., 2007).  The αIIb subunit 
currently has only a handful of binding partners and there has been conflicting 
reports of the function these proteins have in αIIbβ3 activation (Larkin et al., 2004; 
Leung-Hagesteijn, Milankov, Michalak, Wilkins, & Dedhar, 1994; Liu, Corjay, 
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Feuerstein, & Nambi, 2006; Reilly, Larkin, Devocelle, Fitzgerald, & Moran, 2004; 
Vijayan, Liu, Li, & Bray, 2004).   Previously we identified CIB1 in a screen for binding 
partners, and potential regulators, of the αIIb cytoplasmic tail. Initial genetic studies 
of CIB1 function required a megakaryocyte model because only platelets and 
megakaryocytes express the required signaling machinery involved in integrin αIIbβ3 
inside-out activation and platelets are not amenable to direct genetic manipulation 
(Liu et al., 2007).  For a more comprehensive understanding of the role of CIB1 in 
the regulation of integrin αIIbβ3 activation, we developed the Cib1-/- mouse model 
and studied the function of platelets and megakaryocytes derived from these mice.  
We found no significant difference in the protein expression, basal activation or 
agonist-induced activation of αIIbβ3 measured by flow cytometry.  There was also 
no significant difference in aggregation or spreading between platelets from Cib1+/+ 
or Cib1-/- mice.    
 The lack of a phenotype in αIIbβ3 activation in Cib1-/- mice was unexpected 
because our megakaryocytes studies and other independent studies in platelets 
(Naik et al., 2003a; Yuan et al., 2006b; Naik et al., 2003b; Tsuboi, 2002; Vallar et al., 
1999; Yamniuk et al., 2005) demonstrated that CIB1 regulates αIIbβ3 activation and 
platelet spreading.  We suspected that this lack of phenotype in the Cib1-/- platelets 
may be due to a compensatory mechanism that occurred during mouse 
development.  The most obvious possibility would be compensation by another CIB 
family member.  The idea of functional compensation resulting in a limited 
phenotype is not novel.  For example, Vav1 and Vav3 are functionally redundant in 
their role of activating PLC gamma2 (Pearce et al., 2004) and other proteins when 
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knocked down, partially or fully, did not display the platelet phenotype predicted by 
previous short term genetic manipulations (Schraw et al., 2004; Pearce et al., 2004; 
Pearce et al., 2002).  The discrepancies in our previous megakaryocyte results and 
present in vivo results reiterate how fundamentally different chronic genetic 
mutations (knock-out or knock-in) are compared to acute genetic mutations (knock-
down or overexpression).  Both short and long term genetic manipulations provide 
valuable information but the results should be only interpreted under each 
experimental condition. 
   Real time PCR experiments detected an increase in the message of Cib3 
while the message of Cib2 did not change between Cib1+/+ and Cib1-/- in 
megakaryocytes.  Therefore the potential binding of CIB2 and CIB3 to the αIIb tail 
was investigated.  ELISA data indicated that CIBs1-3 can all bind to the cytoplasmic 
tail of αIIb.  The apparent CIB2/αIIb interaction was unexpected since CIB2 was 
demonstrated to not bind αIIb in a yeast two-hybridization assay (Yuan et al., 
2006b).   
 Sequence homology shows that human CIB2, CIB3 and CIB4 are 59%, 62% 
and 64%, homologous to CIB1, respectively (Gentry et al., 2005).  Human CIBs 
show equivalent residues involved in the structure of the hydrophobic binding 
pocket, i.e. the canonical αIIb binding site by sequence alignment (Gentry et al., 
2005).  Currently, only human CIB2 has been reported as a protein in the literature 
(Mayhew et al., 2006); endogenous human or murine CIB3 and CIB4 proteins have 
not been identified to date or studied.    The computer homology modeling analyses 
of CIB proteins provide insights into potential conserved αIIb binding domains in 
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CIB1-3 that support our protein binding data.   We observed a highly conserved 
hydrophobic binding pocket in all CIBs1-3 protein.  CIB1 is reported to undergo 
displacement of its C-terminus upon αIIb binding, which increases the size of the 
hydrophobic binding pocket (Yamniuk et al., 2006).  Removal of the corresponding 
C-terminal residues in CIB2 and CIB3 also led to an increase in the size of the 
hydrophobic binding pocket.  The residues exposed by displacement of the tail were 
also highly conserved between CIB1, -2 and -3.  This theoretical structural change 
could potentially allow CIB2 and CIB3 to share binding partners with CIB1, e.g. 
integrin αIIbβ3. 
 It will be interesting to determine if any other tissues or cells types in the Cib1-
/- mice have altered CIB family protein expression.  It is known that the chronic loss 
of CIB1 affects spermatogenesis (Yuan et al., 2006a) and angiogenesis (Zayed et 
al., 2007) in the Cib1-/- mice.  This begs the question of why some cell types or 
processes may have developed compensatory mechanisms, while other cells did 
not.  For example, endothelial cells isolated from the Cib1-/- mice do not have fully 
functional compensatory mechanisms, as they have decreased migration in culture 
and in vivo these mice have defects in ischemia-induced pathologic angiogenesis 
(Zayed et al., 2007). Also of interest is the question of how many binding partners 
are shared by CIB1, -2 and -3?  Since the functional role of the CIB family in vivo 
has not been established, the development of investigational tools such as 
expression plasmids and antibodies to other CIB family proteins will aid the 
investigation of CIB protein function and regulation.   
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Figure 3.1 Platelet morphology of Cib1-/- mice.  (A)  CIB1 is absent in platelets 
isolated from the Cib1-/- mice.  Platelet lysates from Cib1+/+, Cib1+/- and Cib1-/- mice 
were subjected to Western blotting and CIB1 expression was compared.  GAPDH 
was used as a loading control.  (B)  Surface receptor expression on Cib1-/- platelets 
is similar to expression on Cib1+/+ platelets.   To detect surface receptor expression, 
washed platelets were incubated with FITC-αIIb antibody, FITC-α2 antibody or 
FITC-IgG control for 30 min, or FITC-GP1b antibody or FITC-IgG for 15 min at RT.  
Flow cytometry was used to determine mean fluorescence.  Values were normalized 
and presented as fold over IgG control (antibody/control) (N ≥ 9).  (C) Resting 
platelet morphology is normal when examined by electron microscopy.  There was 
no significant difference in size, shape and granule content between Cib1+/+ and 
Cib1-/- platelets.  Scale bar equals 0.2 µM. 
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Figure 3.2 Platelet function is unaffected by the loss of CIB1.  (A) Integrin αIIbβ3 
activation is normal when assessed by flow cytometry.  Washed platelets were 
incubated for 15 min with an αIIbβ3 active conformation specific antibody (JON/A) or 
IgG control.  Basal expression was defined as JON/A binding over IgG control 
binding (JON/A antibody/control antibody).  Agonist-induced activation was 
measured by stimulating platelets with either 10 µM ADP or 0.1 U thrombin and 
expressed as the increase in antibody binding in stimulated divided by nonstimulated 
platelets (stimulated/nonstimulated platelets) (N ≥ 4) .  (B) Platelet aggregation is 
normal in washed Cib1+/+ and Cib1-/- platelets.  Washed platelets were stimulated by 
5 µm ADP (left) or 0.1 mM PAR4 peptide (right) and platelet aggregation traces were 
recorded for 5 min. ).  (For Figure 2C see following page.)   
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Figure 3.2 Platelet function is unaffected by the loss of CIB1. (C) Activation of 
integrin αIIbβ3 on cultured bone marrow derived megakaryocytes was similar 
between Cib1+/+ and Cib1-/- mice when measured by flow cytometry.  
Megakaryocytes were stimulated with increasing concentrations of PAR4 peptide 
(0.5 mM and 1 mM) and binding of Alexa-546 labeled fibrinogen was determined.  
Mean fluorescent intensities were normalized by dividing the stimulated value by the 
unstimulated control (N = 3).  (For Figure 2A-B see previous page.)   
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Figure 3.3 Platelet spreading is normal in the chronic absence of CIB1.  (A) 
Platelets from Cib1+/+ and Cib1-/- mice adhered and spread similarly on immobilized 
BSA or fibrinogen.  Cib1-/- platelets did not respond differently in the presence or 
absence 100 µM ADP compared to Cib1+/+ platelets.  Platelets were allowed to 
spread for 60 min at 37°C.  Scale bar = 1 µm.  Platelet size (B) and count (C) were 
analyzed by ImagePro software and compared between Cib1+/+ and Cib1-/-.  There 
was no significant difference between the two genotypes. 
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Figure 3.4 CIB family members interact with integrin αIIbβ3.  (A) Cib1-/- mice 
have significantly increased CIB3 mRNA in megakaryocytes derived from bone 
marrow stem cells as measured by quantitative PCR, while CIB2 retains the same 
level of expression as Cib1+/+.  Gapdh was the housekeeping gene used to 
normalize CT values.  Fold values were defined using the ∆∆Ct calculation (Livak et 
al., 2001; Schefe et al., 2006).  Fold value of 1 equates to no change in expression, 
while values above 1 equals increase in message and values below 1 equal 
decrease in message expression (N ≥ 5).  (B)  CIB1-3 proteins bind to integrin αIIb 
peptide as measured by ELISA.  Peptides of the cytoplasmic tail of integrin subunit 
αIIb (αIIb) or control scrambled (scr) peptide were immobilized and increasing 
concentrations of CIB1,-2 or -3 were added to peptide or BSA coated wells.  Data 
graphed is a representative experiment of OD 490 (nm) values of peptide coated 
wells minus non-specific binding (N = 3).  (For Figure 3C see following page.)  
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Figure 3.4 CIB family members interact with integrin αIIbβ3.  (C) Soluble peptide 
competition ELISAs demonstrate that the CIB1-3 interaction with αIIb peptide is 
specific.  Increasing concentrations of soluble αIIb peptide were incubated with 
CIB1, -2, -3 or control protein, calmodulin-like 3, for 30 min.  Samples were added to 
immobilized αIIb peptide or BSA coated wells.  Data is presented as in (B) (N = 3).  
(For Figure 3A-B see previous page.)  
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Figure 3.5 Computer modeling of CIB family proteins reveals a highly 
conserved hydrophobic binding pocket. (A) Homology map of CIB proteins.  
Grey represents non-conserved residues, purple represents conserved, yellow 
represents conserved residues in the hydrophobic binding pocket and orange 
represents non-conserved residue in the hydrophobic binding pocket.  (B) Model of 
CIB after displacement of the C-terminal tail.  Molecular surfaces are represented as 
in (A). 
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CHAPTER 4 
CONCLUDING REMARKS 
   
 When I started working with the Cib1-/- mice, studies had been previously 
published proposing that CIB1 was a negative regulator of agonist-induced αIIbβ3 
activation in megakaryocytes (Yuan et al., 2006).  These earlier experiments 
required the use of genetically altered murine megakaryocytes because direct 
genetic manipulation of anucleate platelets was impossible and the knockout was 
proving to be trickier than expected to generate.  Once the Cib1-/- mouse colony was 
backcrossed 9-10 generations, Dr. Weiping Yuan (who made the knockout with the 
help of Dr. Nobuyo Maeda) and I began to study the Cib1-/- mice to determine if the 
chronic loss of CIB1 altered hemostasis.  We wanted to compare the phenotype of 
megakaryocytes with an acute knockdown of CIB1 to the phenotype of 
megakaryocytes from Cib1-/- mice cultured under the same conditions, but forced to 
mature and adapt while chronically deprived of CIB1 (and the phenotype of platelets 
from knockout mice) relative to agonist-induced activation of αIIbβ3.  We also 
interested in exploring beyond the platelet and megakaryocyte and understand how 
the chronic loss of CIB1affects hemostasis.  As it turned out, this led to a very 
serendipitous expansion of my research project.  
 
4.1  CIB1 and hemostasis 
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 Plasma analysis of the Cib1-/- mice exposed several significant differences in 
protein levels between the Cib1+/+ and Cib1-/- plasma.  The most notable were the 
increases in von Willebrand factor and soluble P-selectin concentration.  To 
understand the effects of these two pro-thrombotic proteins circulating at higher 
levels in the plasma, we examined bleeding time and arterial thrombus formation in 
both genotypes.  These studies demonstrated no significant difference in thrombus 
formation or stability between the Cib1+/+ and the Cib1-/- mice.  Therefore, the Cib1-/- 
mouse may provide a model for studying the critical range of plasma proteins 
required for normal hemostasis. 
 The Cib1-/- mice because of their increased vWF, yet normal hemostasis, 
provide an excellent research tool for studying von Willebrand Disease.  von 
Willebrand Factor is synthesized in endothelial cells and megakaryocytes.  
Endothelial cells constitutively secrete the smaller less active multimers of vWF, 
while both platelets and endothelial cells store the more active ultra-large vWF 
multimers in granules until cellular activation.  von Willebrand Factor multimerization 
occurs in the Golgi by disulfide bond formation (Purvis et al., 2007).  When large 
multimers of vWF are exocytosed from the cell, they are highly adhesive to platelets 
(Ruggeri, 2007).  Normally, metalloprotease ADAMTS-13 cleaves large vWF as a 
regulatory method to control thrombus formation, because the smaller multimers are 
less adhesive.  Interestingly, high fluid shear stress will also promote platelet 
adhesion to smaller vWF multimers (Choi, Aboulfatova, Pownall, Cook, & Dong, 
2007).  Therefore, the lack of an increase of platelet aggregates that should have 
been visible in my flow cytometry experiments (Chapter 3) implies that the Cib1-/- 
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mice do not have a defect in ADAMTS-13 and do not have high fluid shear stress.  
However, von Willebrand Disease researchers could use these mice to investigate 
the effect of changing ADAMTS-13 activity or arterial shear stress on the plasma 
with above average vWF levels. 
 To fully utilize the Cib1-/- mouse as a vWF research tool, the multimeric size of 
the circulating vWF would need to be determined.  Smaller multimers would suggest 
a change in the constitutively-secreted vWF pathway.  Alternatively, smaller vWF 
multimers could result from an increase in ADAMTS-13 activity.  Conversely, if the 
vWF circulating in the Cib1-/- plasma is larger in multimeric size, this would provide 
information about the critical level of large vWF level that will still enable physiologic 
hemostasis.  The Cib1-/- mouse is valuable to anyone investigating the pathologic 
levels of multimer vWF size and this research is tool towards understanding and 
treating vWD.   
 The fact that Cib1-/- mice have increased levels of soluble P-selectin and yet 
appear to have normal hemostasis is also very intriguing.  The main ligand for P-
selectin, PSGL-1 is expressed mainly on leukocytes but is also found on the platelet 
surface (Frenette et al., 2000; Mayadas, Johnson, Rayburn, Hynes, & Wagner, 
1993).  The soluble form of P-selectin still binds PSGL-1 (Frenette et al., 2000; 
Hrachovinova et al., 2003; Mehta, Patel, Laue, Erickson, & McEver, 1997) and could 
therefore compete with the cell surface-bound P-selectin for PSGL-1.  Exploring 
leukocyte interactions with the endothelium or as part of platelet aggregate formation 
may provide additional answers to the potential effect(s) of increased sP-selectin.   
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 Several studies have investigated the role of sP-selectin and vWF, in sync, to 
promote both physiologic and pathologic thrombus formation by involving leukocytes 
(Denis, Andre, Saffaripour, & Wagner, 2001; Dole, Bergmeier, Mitchell, 
Eichenberger, & Wagner, 2005; Mayadas et al., 1993; McEver, 1992; Pendu et al., 
2006; Wagner, 2005).  For example, experiments by Denis et al., 2001, demonstrate 
that vWF-/- mice had defective P-selectin storage into endothelial cell Weibel-Palade 
bodies and this ultimately resulted in to decreased leukocyte recruitment (Denis et 
al., 2001).  It is quite possible that the role of these increased but still non-
pathological concentrations of vWF and sP-selectin may have a greater effect on 
inflammation than hemostasis.  Leukocyte rolling on the endothelium and platelet 
rolling on vessel-wall-bound leukocytes and endothelium are believed to be 
important components of the inflammatory response to allow these cells to home in 
on sites of infection (Denis et al., 2001; Dole et al., 2005; Hartwell et al., 1998; 
Mayadas et al., 1993; Pendu et al., 2006).  Investigating in vivo leukocyte and 
platelet rolling in Cib1-/- mice could yield some more “CIB surprises”.  Since the 
levels of vWF and sP-selectin are increased, one would hypothesize there would be 
a decrease in leukocyte rolling, and to a lesser degree platelet, rolling.  This would 
result from less available unoccupied PSGL1.  The transient interactions that enable 
platelet rolling are strongly based on vWF-GP1b/IX/V, and collagen-GPVI (see 
Chapter 1 section 2 for additional information).  Increased plasma vWF may inhibit 
GP1b/IX/V binding to ECM-vWF.  Given the increase in both vWF and sP-selectin, in 
vivo rolling experiments would be extremely interesting and informative for the 
hemostasis field. 
 114
 Another fascinating question is how the Cib1-/- mice respond to physiological 
stress.  It has already been shown that physiologic stress to Cib1-/- mice affects 
angiogenesis (Zayed et al., 2007).  Inducing physiologic stress in these mice may 
even expose a hemostatic phenotype.  For example, an interesting and logical 
extension to the study of inflammation in these mice would be to challenge them by 
injecting the endotoxin lipopolysaccharide (LPS).  This would cause an increase in 
several plasma proteins and activate the endothelium.  Hartwell et al. showed 
decreased neutrophil influx into inflamed areas in mice genetically engineered to 
express higher levels of sP-selectin (Hartwell et al., 1998). 
  
4.2  CIB and integrin αIIbβ3 
 As mentioned earlier, CIB1 binds to the cytoplasmic tail of the integrin αIIb  
subunit and previous studies in murine megakaryocytes demonstrated that CIB1 is a 
negative regulator of agonist-induced αIIbβ3 activation (Yuan et al., 2006). Others 
have reported that introducing an inhibitory CIB1 antibody into platelets blocked 
platelet spreading on immobilized fibrinogen (Naik & Naik, 2003).  Therefore, 
combining the effects of our acute changes in megakaryocytes with data showing 
that acute changes affect αIIbβ3 in platelets, along with several in vitro studies 
confirming the interaction between CIB1 and αIIb (Naik, Patel, & Parise, 1997; Naik 
et al., 2003; Shock et al., 1999; Yamniuk & Vogel, 2005), we logically hypothesized 
that the Cib1-/- platelets would behave accordingly.  We analyzed Cib1-/- platelets by 
several different methods; however, no significant difference in basal or agonist-
induced activation or platelet spreading was exhibited by platelets from Cib1-/- mice.  
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This lack of phenotype of Cib1-/- platelets mice was quite a surprise.  And though 
plausible, and cannot be dismissed, it seems unrealistic to conclude that CIB1 when 
present has no function in regulating αIIbβ3 activation.  The possibility that these 
mice adapted to the deprivation of CIB1 by compensatory mechanism(s) during 
development is more likely.   
 We explored the possibility of functional compensation by investigating the 
most homologous CIB1 proteins, CIBs2-4.  Currently, there is minimal information on 
CIBs2-4, which did present a challenge.  However, there were mRNA sequences 
identified that I used to perform quantitative real time PCR experiments.  I 
discovered that mRNA level of CIB1 homologs CIB3 and CIB4 were increased in 
Cib1-/- megakaryocytes compared to Cib1+/+ megakaryocytes.  However, for reasons 
mentioned in Chapter 3, I did not pursue CIB4 for the remaining studies.   I made the 
recombinant proteins of CIBs1-3 and measured in vitro binding to αIIb by ELISA.  My 
results provided evidence that recombinant CIB1, -2 and -3 all bound specifically to 
an αIIb cytoplasmic tail peptide.  Subsequent protein modeling experiments 
validated my data by indicating that CIBs1-3 each have a highly homologous 
hydrophobic binding pocket and residues critical to αIIb binding (Barry et al., 2002; 
Gentry et al., 2005).  Therefore, the potential exists for compensation by these CIB 
family members for loss of CIB1 such that hyper-activatable platelets do not occur, 
which could thereby prevent pathologic thrombus formation in Cib1-/- mice.  
 An interesting side note is that when studying the evolution of CIB for my 
homology searches and with the computer modeling experiments done by Dr. 
Brenda Temple, it became clear that the dominant role of the “ancestral” CIB protein 
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would not be to regulate integrin αIIbβ3.  In fact, a CIB sequence can be identified as 
far back evolutionarily as the worm (Caernorhabditis), while the sequence for the 
integrin subunit αIIb could only be identified as far back as zebrafish (Danio), which 
have both platelets and αIIbβ3.  These observations provide further motivation to 
characterize the Cib1-/- mouse to discover other surprising functions of CIB1 and 
other family members unrelated to integrin αIIbβ3.   
 
4.3  Final thoughts  
 In conclusion, my research provides the scientific community with new 
evidence that establishes the Cib1-/- mouse as a useful model for understanding the 
patho-mechanisms involved in not only hemostasis but also inflammation.  Also, I 
have further demonstrated how acute and chronic experiments may provide differing 
results, which needs to be taken into consideration when evaluating data.  Lastly, I 
have discovered the potential for CIB family proteins to share functions and binding 
partners, which could lead to prospective compensatory mechanisms.  Further 
research is necessary to completely understand the roles of CIB1 and other CIB 
family proteins, but it appears likely that this protein family will have an increasing 
role in hemostasis that will be revealed with additional in depth investigations.  
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